Antibodies produced by a single clone of cells.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Sites on an antigen that interact with specific antibodies.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Antibodies reactive with HIV ANTIGENS.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Established cell cultures that have the potential to propagate indefinitely.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Immunoglobulins produced in a response to FUNGAL ANTIGENS.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
The sum of the weight of all the atoms in a molecule.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Proteins prepared by recombinant DNA technology.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.
A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Substances elaborated by bacteria that have antigenic activity.
Substances that are recognized by the immune system and induce an immune reaction.
Substances elaborated by viruses that have antigenic activity.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labeled with fluorescein-conjugated anti-immunoglobulin antibody. (From Bennington, Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.
Antibodies obtained from a single clone of cells grown in mice or rats.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
Antibodies elicited in a different species from which the antigen originated. These antibodies are directed against a wide variety of interspecies-specific antigens, the best known of which are Forssman, Hanganutziu-Deicher (H-D), and Paul-Bunnell (P-B). Incidence of antibodies to these antigens--i.e., the phenomenon of heterophile antibody response--is useful in the serodiagnosis, pathogenesis, and prognosis of infection and latent infectious states as well as in cancer classification.
An encapsulated lymphatic organ through which venous blood filters.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
Techniques for removal by adsorption and subsequent elution of a specific antibody or antigen using an immunosorbent containing the homologous antigen or antibody.
A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.
Antibodies that can catalyze a wide variety of chemical reactions. They are characterized by high substrate specificity and share many mechanistic features with enzymes.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.
Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
Glycoproteins found on the membrane or surface of cells.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Elements of limited time intervals, contributing to particular results or situations.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
The rate dynamics in chemical or physical systems.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate.
The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Field of chemistry that pertains to immunological phenomena and the study of chemical reactions related to antigen stimulation of tissues. It includes physicochemical interactions between antigens and antibodies.
Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen.
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed)
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Adherence of cells to surfaces or to other cells.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed)
Proteins found in any species of virus.
Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Microscopy in which the samples are first stained immunocytochemically and then examined using an electron microscope. Immunoelectron microscopy is used extensively in diagnostic virology as part of very sensitive immunoassays.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A group of replication-defective viruses, in the genus GAMMARETROVIRUS, which are capable of transforming cells, but which replicate and produce tumors only in the presence of Murine leukemia viruses (LEUKEMIA VIRUS, MURINE).
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
A general term for various neoplastic diseases of the lymphoid tissue.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
The phenomenon of immense variability characteristic of ANTIBODIES. It enables the IMMUNE SYSTEM to react specifically against the essentially unlimited kinds of ANTIGENS it encounters. Antibody diversity is accounted for by three main theories: (1) the Germ Line Theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; (2) the Somatic Mutation Theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and (3) the Gene Rearrangement Theory, which holds that antibody diversity is generated by the rearrangement of IMMUNOGLOBULIN VARIABLE REGION gene segments during the differentiation of the ANTIBODY-PRODUCING CELLS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997)
The degree of similarity between sequences of amino acids. This information is useful for the analyzing genetic relatedness of proteins and species.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen.
Polysaccharides found in bacteria and in capsules thereof.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).
One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa.
EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
Transport proteins that carry specific substances in the blood or across cell membranes.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Common name for the species Gallus gallus, the domestic fowl, in the family Phasianidae, order GALLIFORMES. It is descended from the red jungle fowl of SOUTHEAST ASIA.
Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques.
The marking of biological material with a dye or other reagent for the purpose of identifying and quantitating components of tissues, cells or their extracts.
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Transplantation between animals of different species.
Single-stranded complementary DNA synthesized from an RNA template by the action of RNA-dependent DNA polymerase. cDNA (i.e., complementary DNA, not circular DNA, not C-DNA) is used in a variety of molecular cloning experiments as well as serving as a specific hybridization probe.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Acquired defect of cellular immunity that occurs in mice infected with mouse leukemia viruses (MuLV). The syndrome shows striking similarities with human AIDS and is characterized by lymphadenopathy, profound immunosuppression, enhanced susceptibility to opportunistic infections, and B-cell lymphomas.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. (1/2033)

PURPOSE: Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; however, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood. METHODS AND RESULTS: After the observation at our institution of a rapid reduction of peripheral-blood tumor cells with associated severe pulmonary infusion-related toxicity in two patients with refractory hematologic malignancies, data on three additional cases were collected from physician-submitted reports of adverse events related to rituximab treatment. Five patients with hematologic malignancies possessing a high number of blood tumor cells were treated with rituximab and developed rapid tumor clearance. The median age was 68 years (range, 26 to 78 years). Patients were diagnosed with B-cell prolymphocytic leukemia (n = 2), chronic lymphocytic leukemia (n = 2), or transformed non-Hodgkin's lymphoma (n = 1). All of these patients had bulky adenopathy or organomegaly. All five patients developed a unique syndrome of severe infusion-related reactions, thrombocytopenia, rapid decrement in circulating tumor cell load, and mild electrolyte evidence of tumor lysis, and all required hospitalization. In addition, one patient developed ascites. These events resolved, and four patients were subsequently treated with rituximab without significant complications. CONCLUSION: Rituximab administration in patients who have a high number of tumor cells in the blood may have an increased likelihood of severe initial infusion-related reactions. These data also suggest that rituximab may have activity in a variety of other lymphoid neoplasms, such as chronic lymphocytic leukemia and B-cell prolymphocytic leukemia.  (+info)

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. (2/2033)

Rituximab is a chimeric antibody with human gamma-1 and kappa constant regions and murine variable regions. It recognizes the CD20 antigen, a pan B-cell marker. Therapeutic trials in patients with B-cell non-Hodgkin's lymphoma (NHL) have shown significant efficacy with a primary response rate of 50%, and a secondary response rate of 44% after repeat treatments in prior responders. The selection for proliferating tumor cells that no longer express CD20 may compromise repeated treatment. We have identified a patient who developed a transformed NHL that lost CD20 protein expression after two courses of therapy with rituximab. In a pretreatment lymph node biopsy, 83% of B cells (as defined by CD19 and surface immunoglobulin) expressed surface CD20. A biopsy from the recurrent tumor after two courses of rituximab revealed a diffuse large cell NHL where 0% of B cells expressed CD20 with no evidence of bound rituximab. Cytoplasmic staining showed no CD20 protein. Sequencing of immunoglobulin heavy chain cDNA identified identical variable sequences in the initial and recurrent lymphomas, confirming the association between the two tumors. Literature and database review suggests that approximately 98% of diffuse large cell lymphomas express CD20, which suggests that these tumors rarely survive without CD20. This is the first identified case of loss of CD20 expression in a lymphoma that has relapsed after rituximab therapy, although several other cases have since been identified. Considering the significant number of patients treated with anti-CD20 antibodies, this may occur only rarely and is unlikely to preclude recurrent therapy with anti-CD20 antibodies in the majority of patients. However, because many patients have relapsed after anti-CD20 antibody therapy and have not been biopsied to identify clones with down-regulated CD20 antigen, we do not currently know the true frequency of this phenomenon. When possible, patients should undergo evaluation for CD20 expression before repeated courses of anti-CD20 therapy.  (+info)

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. (3/2033)

BACKGROUND: Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen which has been utilized for therapy of B-cell non-Hodgkin's lymphoma (NHL). A previous clinical trial demonstrated that treatment with four weekly doses of 375 mg/m2 of Rituximab in patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma was well tolerated and had significant clinical activity. PATIENTS AND METHODS: To assess the safety and efficacy of Rituximab treatment, an open-label, single-arm, multi-center, phase II study of eight consecutive weekly infusions of 375 mg/m2 Rituximab in patients with low-grade or follicular B-cell NHL who had relapsed or had failed primary therapy was conducted. Thirty-seven patients with a median age of 55 years were treated. RESULTS: Grade 1 or 2 adverse events were the majority of reported toxicities and occurred most frequently with the first infusion, decreasing with subsequent infusions. No patients developed a host antibody response (HACA) to Rituximab. The mean serum immunoglobulin levels for IgG, IgA, and IgM stayed within the normal range throughout the study. The majority of patients who were bcl-2 positive at baseline in peripheral blood became bcl-2 negative during treatment and remained negative at the time of B-cell recovery. In the 37 intent-to-treat patients, 5 (14%) had a complete response and 16 (43%) had a partial response for an overall response rate of 57%. Of 35 evaluable patients, 21 (60%) responded to treatment (14% CR and 46% PR). In responders, the median time to progression (TTP) and the median response duration have not been reached after 19.4+ months and 13.4+ months, respectively. CONCLUSIONS: The safety profile and efficacy achieved in this pilot study of extended treatment with Rituximab compares favorably with those seen with four weekly doses. Further studies are warranted to investigate whether this or other extended Rituximab schedules will result in increased efficacy in all or in certain subgroups of patients with low-grade or follicular NHL.  (+info)

Use of Sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukoscintigraphy. (4/2033)

Diabetic patients suspected of having osteomyelitis secondary to foot ulcers underwent scintigraphic imaging with Sulesomab, an anti-granulocyte antibody Fab' fragment labeled with technetium-99m. Among 122 patients who had osteomyelitis confirmed or excluded by histopathologic and/or microbiologic techniques, Sulesomab had a 91% sensitivity, a 56% specificity, and an accuracy of 80%. One planar imaging session was usually sufficient for diagnosis, typically requiring 20-30 minutes of camera time 1-2 hours after injection. Compared with ex vivo autologous white blood cell (WBC) scans, Sulesomab performed comparably but with significantly greater sensitivity (92% vs. 79%; P < .05). Sulesomab results were more sensitive than radiography (90% vs. 62%; P < .05) and more specific than bone scans (50% vs. 21%; P < .05) and would have altered management plans in most patients. No related adverse events occurred, and there was no induction of human anti-mouse antibody. Sulesomab is an effective and rapid imaging agent that is diagnostically comparable or superior to WBC scans in this setting, with significant advantages in safety and ease of use.  (+info)

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. (5/2033)

PURPOSE: To determine the safety and efficacy of the combination of the chimeric anti-CD20 antibody, Rituxan (Rituximab, IDEC-C2B8; IDEC Pharmaceuticals Corporation, San Diego, CA), and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. PATIENTS AND METHODS: Forty patients with low-grade or follicular B-cell non-Hodgkin's lymphoma received six infusions of Rituxan (375 mg/m2 per dose) in combination with six doses of CHOP chemotherapy. RESULTS: The overall response rate was 95% (38 of 40 patients). Twenty-two patients experienced a complete response (55%), 16 patients had a partial response (40%), and two patients, who received no treatment, were classified as nonresponders. Medians for duration of response and time to progression had not been reached after a median observation time of 29 + months. Twenty-eight of 38 assessable patients (74%) continued in remission during this median follow-up period. The most frequent adverse events attributable to CHOP were alopecia (38 patients), neutropenia (31 patients), and fever (23 patients). The most frequent events attributed to Rituxan were fever and chills, observed primarily with the first infusion. No quantifiable immune response to the chimeric antibody was detected. In a subset of 18 patients, the bcl-2 [t(14;18)] translocation was positive in eight patients; seven of these patients had complete remissions and converted to polymerase chain reaction (PCR) negativity by completion of therapy. CONCLUSION: This is the first report demonstrating the safety and efficacy of Rituxan anti-CD20 chimeric antibody in combination with standard-dose systemic chemotherapy in the treatment of indolent B-cell lymphoma. The clinical responses suggest an additive therapeutic benefit for the combination with no significant added toxicity. The conversion of bcl-2 from positive to negative by PCR in blood and/or marrow suggests possible clearing of minimal residual disease not previously demonstrated by CHOP chemotherapy alone.  (+info)

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. (6/2033)

We evaluated the response and toxicity of rituximab in the setting of progressive intermediate grade non-Hodgkin's lymphoma (NHL) after autologous peripheral stem cell transplantation (PSCT). Seven patients with a median age of 59 years (45-62), ECOG performance status 0-1, and CD20-positive diffuse large cell lymphoma with progression after PSCT were treated. All patients initially received 4-weekly infusions of rituximab (375 mg/m2). The maximum response was three CR and four PR. Median progression-free survival was 197 days (range 60-282). With a median follow-up of 204 (115-299) days, the patients' disease status is classified as two CR, one PR, and four PD. Four of five patients with ECOG performance status of 1 prior to treatment showed improvement to status 0 after treatment with rituximab. While follow-up is short, these results suggest that rituximab has significant activity in intermediate-grade non-Hodgkin's lymphoma that has relapsed after PSCT.  (+info)

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). (7/2033)

Eleven patients with relapsed fludarabine-resistant B-cell chronic lymphocytic leukemia (CLL) or leukemic variants of low-grade B-cell non-Hodgkin's lymphoma (NHL) were treated with the chimeric monoclonal anti-CD20 antibody rituximab (IDEC-C2B8). Peripheral lymphocyte counts at baseline varied from 0.2 to 294.3 x 10(9)/L. During the first rituximab infusion, patients with lymphocyte counts exceeding 50.0 x 10(9)/L experienced a severe cytokine-release syndrome. Ninety minutes after onset of the infusion, serum levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) peaked in all patients. Elevated cytokine levels during treatment were associated with clinical symptoms, including fever, chills, nausea, vomiting, hypotension, and dyspnea. Lymphocyte and platelet counts dropped to 50% to 75% of baseline values within 12 hours after the onset of the infusion. Simultaneously, there was a 5-fold to 10-fold increase of liver enzymes, d-dimers, and lactate dehydrogenase (LDH), as well as a prolongation of the prothrombin time. Frequency and severity of first-dose adverse events were dependent on the number of circulating tumor cells at baseline: patients with lymphocyte counts greater than 50.0 x 10(9)/L experienced significantly more adverse events of National Cancer Institute (NCI) grade III/IV toxicity than patients with less than 50.0 x 10(9)/L peripheral tumor cells (P = .0017). Due to massive side effects in the first patient treated with 375 mg/m(2) in 1 day, a fractionated dosing schedule was used in all subsequent patients with application of 50 mg rituximab on day 1, 150 mg on day 2, and the rest of the 375 mg/m(2) dose on day 3. While the patient with the leukemic variant of the mantle-cell NHL achieved a complete remission (9 months+) after treatment with 4 x 375 mg/m(2) rituximab, efficacy in patients with relapsed fludarabine-resistant B-CLL was poor: 1 partial remission, 7 cases of stable disease, and 1 progressive disease were observed in 9 evaluable patients with CLL. On the basis of these data, different infusion schedules and/or combination regimens with chemotherapeutic drugs to reduce tumor burden before treatment with rituximab will have to be evaluated.  (+info)

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. (8/2033)

PURPOSE: A phase II trial was performed to evaluate the safety and efficacy of rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with bulky (> 10-cm lesion) relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Thirty-one patients received intravenous infusions of rituximab 375 mg/m(2) weekly for four doses. All patients had at least one prior therapy (median, three; range, one to 13) and had progressive disease at study entry. Patients were a median of 4 years from diagnosis. RESULTS: No patient had treatment discontinued because of an adverse event. No patient developed human antichimeric antibody. The overall response rate in 28 assessable patients was 43% with a median time to progression of 8.1 months (range, 4.5 to 18.6+ months) and median duration of response of 5.9 months (range, 2.8 to 12.1+ months). The average decrease in lesion size in patients who achieved a partial response was 76%, and patients with stable disease had a decrease in average lesion size of 26%. Median serum antibody concentration was higher in responders compared with nonresponders, and a negative correlation was shown between antibody concentration and tumor bulk at baseline. CONCLUSION: Rituximab single-agent outpatient therapy is safe and shows significant clinical activity in patients with bulky relapsed or refractory low-grade or follicular B-cell NHL.  (+info)

TY - JOUR. T1 - VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma. T2 - A Wisconsin Oncology Network study. AU - Chang, Julie E.. AU - Peterson, Christopher. AU - Choi, Sangbum. AU - Eickhoff, Jens C.. AU - Kim, Kyungmann. AU - Yang, David T.. AU - Gilbert, Leslie A.. AU - Rogers, Eric S.. AU - Werndli, Jae E.. AU - Huie, Michael S.. AU - Mcfarland, Thomas A.. AU - Volk, Michael. AU - Blank, Jules. AU - Callander, Natalie S.. AU - Longo, Walter L.. AU - Kahl, Brad S.. PY - 2011/10. Y1 - 2011/10. N2 - Intensive chemotherapy regimens are not feasible in many adults with mantle cell lymphoma (MCL). We sought to build upon our previous experience with a non-intensive regimen, modified R-hyperCVAD chemotherapy (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) with maintenance rituximab (MR), by the incorporation of bortezomib (VcR-CVAD) and the extension of MR beyond 2years. Patients with previously untreated MCL received VcR-CVAD ...
TY - JOUR. T1 - Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma. T2 - Eastern Cooperative Oncology Group study E1499. AU - Smith, Mitchell R.. AU - Li, Hailun. AU - Gordon, Leo. AU - Gascoyne, Randy D.. AU - Paietta, Elisabeth. AU - Forero-Torres, Andres. AU - Kahl, Brad S.. AU - Advani, Ranjana. AU - Hong, Fangxin. AU - Horning, Sandra J.. PY - 2012/9/1. Y1 - 2012/9/1. N2 - Purpose: To test the hypothesis that consolidation therapy with yttrium-90 ( 90Y) -ibritumomab tiuxetan after brief initial therapy with four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated mantle-cell lymphoma would be a well-tolerated regimen that would improve outcomes compared with historical R-CHOP data. Patients and Methods: Patients ≥ 18 years old with histologically confirmed mantle-cell ...
This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-sensitive indolent B-cell non hodgkin lymphoma that has relapsed at least 6 months after completing treatment with single agent rituximab or a rituximab-containing regimen. Subjects must have attained a Complete Response or Partial Response to their last prior rituximab containing therapy lasting at least six months beyond the end of rituximab therapy. Subjects will receive four weekly doses of single agent ofatumumab (1000 mg) or rituximab (375 mg/m2), followed by ofatumumab (1000 mg) or rituximab (375 mg/m2) every 2 months for four additional doses. Therefore, subjects will receive a total of eight doses of anti-CD20 antibody over 9 months. Subjects will be evaluated for response after completion of the first four doses of therapy, after six doses of therapy, and after completion of study therapy. ...
This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-sensitive indolent B-cell non hodgkin lymphoma that has relapsed at least 6 months after completing treatment with single agent rituximab or a rituximab-containing regimen. Subjects must have attained a Complete Response or Partial Response to their last prior rituximab containing therapy lasting at least six months beyond the end of rituximab therapy. Subjects will receive four weekly doses of single agent ofatumumab (1000 mg) or rituximab (375 mg/m2), followed by ofatumumab (1000 mg) or rituximab (375 mg/m2) every 2 months for four additional doses. Therefore, subjects will receive a total of eight doses of anti-CD20 antibody over 9 months. Subjects will be evaluated for response after completion of the first four doses of therapy, after six doses of therapy, and after completion of study therapy. ...
Key clinical point: The incidence of late-onset neutropenia proved higher than previously found in rituximab-treated patients with autoimmune diseases.Major finding: At 1, 2, and 5 years of continuous B-cell depletion, the incidence of late-onset neutropenia was 6.6% (95% confidence interval, 5.0%-8.7%), 7.9% (95% CI, 6.1%-10.2%), and 13.5% (95% CI, 10.4%-17.4%), respectively.Study details: A retrospective cohort study of 738 patients with various autoimmune diseases who were treated with rituximab.
The treatment of non-Hodgkin lymphoma (NHL) patients has been recently informed by several important studies, which were discussed at the Best of ASCO Boston meeting by Michael E. Williams, MD, of the University of Virginia Cancer Center in Charlottesville.. Bendamustine Outperforms R-CHOP in NHL In a presentation at this years ASCO Annual Meeting Plenary Session, German investigators reported that in the phase III Study Group Indolent Lymphomas (StiL) NHL1 trial, the combination of bendamustine (Treanda) plus rituximab (Rituxan), or BR, more than doubled the median progression-free survival vs standard treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and proved more tolerable as well in patients with NHL.1 While B-R has been a recommended treatment option by the National Comprehensive Cancer Network since the initial study data were announced in 2009, many U.S. oncologists have not yet utilized the regimen.. The updated StiL NHL1 results will likely ...
We thank Dr Wallace et al for their response to our recently published article Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis, highlighting some methodological limitations of our study.1 2 One of the limitations mentioned by Wallace and colleagues is the inclusion of incident and prevalent cases and since only 15 out of 192 patients were incident cases, generalisability of our findings for this subset of patients may not be possible. We agree that the use of immunosuppression prior to initiation of rituximab likely confers a risk to develop infectious complications after rituximab administration. Cyclophosphamide was used to control disease in 62 patients the year before rituximab was initiated. Among these, 53 patients had no severe infection (median cyclophosphamide exposure 7 g, range 0.66-45 g), while 9 patients receiving cyclophosphamide the index year before had a severe ...
We thank Dr Wallace et al for their response to our recently published article Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis, highlighting some methodological limitations of our study.1 2 One of the limitations mentioned by Wallace and colleagues is the inclusion of incident and prevalent cases and since only 15 out of 192 patients were incident cases, generalisability of our findings for this subset of patients may not be possible. We agree that the use of immunosuppression prior to initiation of rituximab likely confers a risk to develop infectious complications after rituximab administration. Cyclophosphamide was used to control disease in 62 patients the year before rituximab was initiated. Among these, 53 patients had no severe infection (median cyclophosphamide exposure 7 g, range 0.66-45 g), while 9 patients receiving cyclophosphamide the index year before had a severe ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). This new treatment includes the same monoclonal antibody as intravenous Rituxan® (rituximab) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.. With todays approval of Rituxan Hycela, people with three of the most common blood cancers now have a new treatment option which provides efficacy comparable with intravenous Rituxan and can be delivered under the skin in minutes instead of hours through IV infusion, said Sandra Horning, MD, Roches Chief Medical Officer and Head ...
Paediatric onset multiple sclerosis (POMS) is characterized by high inflammatory activity. No disease modifying treatment has been approved for POMS. The objective of this report was to report the use of rituximab, a B cell depleting monoclonal anti-CD20-antibody, in POMS. This is a retrospective case series at four specialized MS centres in Sweden. Participants were identified through the Swedish MS-registry and our own patient stocks. Data were collected through medical charts review. We identified 14 POMS patients treated with i.v. rituximab 500-1000 mg every 6th to 12th months. Median age at disease onset was 14.7 years, median age at rituximab treatment initiation was 16.5 years, and median treatment duration was 23.6 months. No relapses were reported, and the EDSS scores remained stable or decreased in 13 of 14 cases during rituximab treatment. Beyond 6 months from initiating rituximab treatment, only one new lesion was detected on MRI. No serious AEs were reported. The drug survival was ...
The treatment of patients with non-Hodgkins lymphoma (NHL) may be complicated by concomitant chronic hepatitis C virus (HCV) infection. Recent data suggest that HCV may also be a contributing factor to the development of this disease. Although antiviral treatment has occasionally been reported to result in the regression of lymphoma in patients with HCV infection, the importance of the control of this infection on the prognosis of lymphoma needs to be defined. Here we report a patient with diffuse large B-cell lymphoma who presented with a mass in her left breast. She had had HCV-related liver cirrhosis for 6 years. She was given rituximab monotherapy for three consecutive weeks, but treatment had to be discontinued as a result of hematological toxicity. HCV viral load also increased, but then decreased gradually after rituximab was stopped. She could be given no further therapy. Six months later she presented with spinal involvement with infiltration of the cauda equina. Though cranial-spinal ...
Rituximab (RTX) may favorably affect skin and lung fibrosis in patients with systemic sclerosis (SSc); however, the underlying molecular mechanisms remain unknown. We aimed to explore the hypothesis that RTX may mediate its antifibrotic effects by regulating the expression of Dickkopf-1 (Dkk-1), an inhibitor of the Wnt pathway. Fourteen patients with SSc and five healthy subjects were recruited. Dkk-1 expression was immunohistochemically assessed in skin biopsies obtained from 11 patients with SSc (8 treated with RTX and 3 with standard treatment), whereas DKK1 gene expression was assessed in 3 patients prior to and following RTX administration. In baseline biopsies obtained from all patients with SSc but not in healthy subjects, Dkk-1 was undetectable in skin fibroblasts. Following RTX treatment, four out of eight patients had obvious upregulation of Dkk-1 skin expression. Similarly, RTX treatment correlated with a significant 4.8-fold upregulation of DKK1 gene expression (p = 0.030). In contrast,
Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with...
In the clinic, BCDT can markedly ameliorate the course of autoimmune diseases in patients, but the mechanisms underlying these beneficial effects are poorly understood, as they are thought, in many cases, to operate irrespective of autoantibody levels. Here, we demonstrate that IL-6 production is the major mechanism of B cell-mediated pathogenesis during EAE, and we show that this inflammatory pathway is markedly increased in RR-MS patients. Autoantibody levels were unaffected by IL-6 production by B cells. This is the first demonstration of a nonantibody-mediated mechanism of B cell pathogenesis in EAE and MS. Remarkably, the elevated production of IL-6 by B cells from MS patients was effectively normalized by Rituximab treatment. In both patients and mice the reduced disease severity after B cell depletion was accompanied by a decrease in the autoreactive Th17 response, and so we believe that B cells are making an all-important contribution to the IL-6-dependent promotion of pathogenic Th17 ...
Background: The PRIMA study showed that 2 years of R-M therapy after immunochemotherapy as first line treatment of follicular lymphoma reduced the risk of disease progression compared to OBS (Salles et al, Lancet 2011). Per-protocol analyses showed that R-M did not adversely affect patient-reported quality of life.
The present study showed that, in patients with HIV-related DLBCL, immunochemotherapy with R-CHOP with concomitant administration of HAART is feasible, safe and effective. The main prognostic factors were related to the lymphoma itself. In addition, this is the first study to confirm the favourable impact of virological response to HAART in the survival of patients treated with rituximab-based CHT.. The design of this study took into account the promising results observed with standard CHOP CHT in patients with ARL in the HAART era (Coiffier et al, 2002; Pfreundschuh et al, 2006). As immunochemotherapy with rituximab in combination with CHOP-based or infusional regimens has shown good results in non-immunosuppressed patients with DLBCL, we developed the present phase II trial of R-CHOP in this particular subtype of lymphoma in patients with HIV infection, in whom the safety and efficacy were unknown. In fact, to date, only two phase II studies with immunochemotherapy (Spina et al, 2005; Boue et ...
I think the new pms-rituxan studies are exploring the possibility that the treatment failed because IV administration barely penetrates the cns. The assumption is that it works in rrms because the bbb is open and therefore the rituxan can get into the cns. I believe this logic is also part of the suitability criteria for hsct relapses, no joy or something like that. The new studies all have an IT component. There is conflicting information out there regarding the usefulness of rituxan in the cns. Some claim the cns B cells arent cleared out by IT rituxan. Others claim they do. Based on successful use of IT rituxan for CNS lymphomas that were NOT managed by IV rituxan, I think the cns B cells are cleaned up by IT rituxan. Im not a doctor though...just a rampant speculator ...
TY - JOUR. T1 - Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma [4]. AU - Ennishi, Daisuke. AU - Yokoyama, Masahiro. AU - Mishima, Yuko. AU - Watanabe, Chie. AU - Terui, Yasuhito. AU - Takahashi, Shunji. AU - Takeuchi, Kengo. AU - Ikeda, Kazuma. AU - Tanimoto, Mitsune. AU - Hatake, Kiyohiko. PY - 2007/11. Y1 - 2007/11. UR - UR - U2 - 10.1080/10428190701636476. DO - 10.1080/10428190701636476. M3 - Article. C2 - 17990181. AN - SCOPUS:36048934446. VL - 48. SP - 2241. EP - 2243. JO - Leukemia and Lymphoma. JF - Leukemia and Lymphoma. SN - 1042-8194. IS - 11. ER - ...
Given the genetic diversity of B-cell lymphomas and differential antigen expression patterns across lymphoma subtypes, it is unlikely that a single small molecule or antibody-based therapeutic will effectively treat all categories of NHL. Therefore, the use of therapeutic antibody combinations targeting different tumor antigens is expected to produce a more robust antitumor response. Simultaneously targeting CD20 and the TNFR family member CD40 may be productive, because both are expressed on the majority of B-cell lymphomas and mediate differential signaling events through their cytoplasmic domains. We evaluated the potential of improving rituximab-based therapies in NHL by targeting CD40 with dacetuzumab. In vivo analysis of the dacetuzumab-rituximab combination in the Ramos NHL xenograft model showed the capacity of dacetuzumab to augment rituximab activity. Potential mechanisms of action behind the ability of dacetuzumab to enhance rituximab activity in vivo include improved recruitment of ...
Merging of two procedures type EU SPC and PIL EMEA/H/C/000165/II/0162 & EMEA/H/C/000165/II/0168 : Roche Initiated - Non CDS - Non Safety. Paediatric study was sole clinical measure in MabThera Paediatric Investigation Plan (PIP) and, as per Paediatric Regulation, a Type II variation had to be submitted for CHMP assessment for the purpose of updating the SmPC with paediatric data. - Type II/162: CDS Update - Non Safety, 31.0, Type II variation to extend the indications (CDS non-safety) for MabThera. 1. Following efficacy and safety data from Clinical study report (CSR) WA25615 (also known as Paediatric Polyangiitis and Rituximab Study [PePRS]) which was conducted to fulfil the measure of the Paediatric Investigational Plan (PIP: EMEA-000308-PIP02-11-M01) agreed upon in the context of rituximab development for treatment of adult patients with GPA and MPA (RAVE study). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and sections 2, 3 and 4 of the Package Leaflet are updated ...
Abstract. The safety and efficacy of rituximab (R) monotherapy is well established and its excellent tolerability makes it an attractive option for maintenance
This study will investigate the efficacy of rituximab IV and seven administrations of rituximab SC (experimental arm) versus four infusions of rituximab IV
Efficacy and safety information from the PePRS Trial, which studied RITUXAN® (rituximab) induction and follow-up treatment of pediatric patients with GPA and MPA. Please see Important Safety Information including Boxed Warning and Full Prescribing Information for more information.
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles).
This 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and intravenous MabThera (rituximab) in patients with follicular
More than 160 key abstracts confirm MabThera/Rituxan as the standard of care in hematological cancers, , , , Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that updated results of the pivotal phase II...
Whether my decisions ultimately are proved wise will be written in these pages. I began using single-agent rituximab (Rituxan) in 2004, adding the steroid methylprednisolone in March 2007 to combat AIHA. In October 2007, after a severe AIHA relapse that left me steroid refractory, I was treated with Rituxan + cyclophosphamide, vincristine, and prednsione (R-CVP). In January 2009, when AIHA and hemolysis of red blood cells returned, I had Rituxan + cyclophosphamide and dexamethasone (R-CD). I used this a few times to control the condition, with shorter and shorter periods until AIHA relapse. Starting in February 2010 I used Arzerra (ofatumumab) and Revlimid (lenalidomide), and then for a year and a half maintained control of the disease -- and the AIHA -- with Revlimid alone. Alas, the Revlimid came at a high price in terms of blood clotting issues, and as of 2012 I was treated with bendamustine and rituximab, which gave me a CR in the marrow and blood, leaving some swollen lymph nodes behind ...
After three months of Chemo, the Fludarabine/Mitoxantrone is really kicking his bone marrow but its not doing a whole lot to the cancerous lymphocytes, so the new plan is to add Rituxan. Rituxan is a monoclonal antibody which specifically targets mature B Lymphocytes (as opposed to ordinary chemo which kills a lot of innocent bystander cells.) This is good news, in my opinion - I was hoping they would try Rituxan soon. But of course, Rituxan has its own sticky wickets, and the first one comes up tomorrow when Dave gets his first dose of Rituxan ...
This finding is in contrast to the more pronounced effect in patients who were RF/anti-CCP seropositive observed in a previous study.11 However, the superior response of patients who were seropositive strengthened over time, as shown by greater decreases in disease activity and enhanced ACR responses at week 48 in rituximab-treated patients who were seropositive compared with patients who were seronegative ...
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with
This prospective, double-blind, placebo-controlled, multi-center, randomized trial will evaluate the effect of rituximab on disease progression in subjects with SSc-PAH receiving concurrent stable-dose standard medical therapy with a prostanoid, endothelin receptor antagonist, and/or phosphodiesterase 5 (PDE-5) inhibitor. The study will focus on assessment of clinical response and safety measures longitudinally. In addition, the effects of treatment with rituximab on the underlying immune mechanisms associated with B-cell dysregulation and pathogenic autoantibody response in this disease will be investigated. 1000 mg of rituximab or placebo will be administered as two IV infusions given two weeks apart. Clinical assessments and sample collection will occur at monthly visits through Week 48. If a participant has not recovered B cells by Week 48, B cell studies will be conducted quarterly until reconstitution is documented or for 2 years after initial treatment. Five patients will be recruited ...
Non-Hodgkins Lymphoma (NHL) is the most common form of the lymphomas. Each form of lymphoma has different biological behaviors and characteristics. Rituximab (Rtxn) is the drug used most commonly in the treatment of NHL. Rtxn has been shown to improve patients survival and delays the developing reoccurrence. Rituximab has been used alone and in the combination with other drugs, like 2cd-A. In previous studies, preformed by this lab, rituximab was tested in combination with 2cd-A in-vivo, and the outcomes were successful. This same combination was then tested invitro and did not have a positive result. It was assumed that the Rtxn drug would not work successfully in:-vitro. In this study we tested different lots of rituximab alone and in combination with 2-CdA oh three different cell lines; and discovered that different lots of rituximab (solo and in combination) are able to be effective on in-vitro lymphoma cells. Of the seven Rtxn lots that were tested, in all three cell lines the drugs used ...
Halozyme Therapeutics and Roche announced initiation of their Phase 3 study of subcutaneous MabThera (rituximab) for the treatment of NHL.
Cost regulators are looking favourably on the use of Roches MabThera on the National Health Service to treat patients with relapsed/refractory forms chronic lymphocytic leukaemia, the most common form of the blood disease. - News - PharmaTimes
Rituximab is a therapy no used in both indolent and aggressive B cell lymphomas. What is the mechanism of action of Rituximab? List the major disorders for which Rituximab is approved for use.. Recall that CD20 is expressed on over 90% of B cells and is a protein that is not shed or internalized.. Rituximab is an anti-CD20 chimeric monoclonal antibody that on contact to CD20 on the surface of a B cell causes cytotoxicity mediated by compliment and antibody-dependent cellular cytotoxicity.. Indications for Rituximab use:. ...
Hi Everyone. What an interesting topic - Ill throw in what I know for now if thats ok?. In the UK were told generally that Rituxan / Rituximab has no side effects except for during the actual infusion process. These effects include flushing, closing of the throat or tight chest sensations, chills, palps and feelings of fever. Also BP can go up or down.. Generally if they slow down the infusion these problems go away. My infusion used to take 6 to 8 hours each time! (everyone else was about 1 - 2 hours). Were told that there should be no after effects other than maybe an elevated Uric Acid level as the Rituxan kills off the bad cells and the body trys to flush them out - were usually given an Anti-Gout medication here (allopurinol) to counter act those effects.. Its interesting that you all speak of a rash and itching sensation as I had that really badly twice in the last year BUT have been off Rituxan for over 2 years! My GP said it was an allergic reaction to something and since a new ...
D02994 Rituximab (USAN/INN); Rituximab (genetical recombination) (JAN); Rituximab (genetical recombination) [Rituximab biosimilar 1] (JAN ...
Bulgular: Rituksimab tedavisinin ba lad s rada ortalama ya ( SD) 46,6 11,3 y ld r. Rituksimab tedavisi ncesinde ortalama trombosit say s ( SD) 17,400 8878/mm3 d r. Erken ve ge yan t edilen olgularda rituksimab ba lang c ile yan ta kadar ge en ortalama s re ( SD) s ras yla 1,8 1,3 hafta ve 10 2,8 hafta olarak saptanm t r. EY ve GY elde edilen olgularda ortalama yan t s resi s ras yla 51 47,2 ay ve 6 4,2 ayd r. On be olgunun 7 sinde (%46,7) rituximab tedavisine ba lang ta yan t elde edilmi tir (5 EY, 2 GY). SY oran %26,7 dir (4/15). Rituksimab tedavisine yan t veren olgular aras nda 3 (3/7, %42,9) yan t n bir y ldan fazla ve 2 si (2/7, %28,6) yan t n 5 y ldan fazla s rd rm t r. Yedi olgunun ikisi (%28,6) rituksimab ba lang c ndan 98 ay sonra halen yan t n korumaktad r. Ba lang ta yan t veren 5 olgunun hepsi relaps sonras nda ard k tedavilere yan t vermi tir (3 TY, 2 PY ...
Bulgular: Rituksimab tedavisinin ba lad s rada ortalama ya ( SD) 46,6 11,3 y ld r. Rituksimab tedavisi ncesinde ortalama trombosit say s ( SD) 17,400 8878/mm3 d r. Erken ve ge yan t edilen olgularda rituksimab ba lang c ile yan ta kadar ge en ortalama s re ( SD) s ras yla 1,8 1,3 hafta ve 10 2,8 hafta olarak saptanm t r. EY ve GY elde edilen olgularda ortalama yan t s resi s ras yla 51 47,2 ay ve 6 4,2 ayd r. On be olgunun 7 sinde (%46,7) rituximab tedavisine ba lang ta yan t elde edilmi tir (5 EY, 2 GY). SY oran %26,7 dir (4/15). Rituksimab tedavisine yan t veren olgular aras nda 3 (3/7, %42,9) yan t n bir y ldan fazla ve 2 si (2/7, %28,6) yan t n 5 y ldan fazla s rd rm t r. Yedi olgunun ikisi (%28,6) rituksimab ba lang c ndan 98 ay sonra halen yan t n korumaktad r. Ba lang ta yan t veren 5 olgunun hepsi relaps sonras nda ard k tedavilere yan t vermi tir (3 TY, 2 PY ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
TY - JOUR. T1 - Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. AU - Kim, Seok Jin. AU - Lee, Seung Jin. AU - Choi, In Young. AU - Park, Yong. AU - Choi, Chul Won. AU - Kim, In Sun. AU - Yu, Woosung. AU - Hwang, Hee Sang. AU - Kim, Byung Soo. PY - 2008/9. Y1 - 2008/9. N2 - Objectives: B-cell activating factor of the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) regulate survival and proliferation of B cells. Thus the association of elevated serum levels of BAFF and APRIL with worse prognosis has been suggested in B-cell lymphoid malignancies. However, the prognostic relevance of BAFF and APRIL is unknown in patients treated with rituximab, a monoclonal antibody targeting B-cell depletion. Methods: We measured serum levels of BAFF and APRIL by enzyme-linked immunosorbent assay in 66 patients newly diagnosed as diffuse large B-cell lymphoma (DLBCL). All patients were treated ...
MZL is a rare type of malignant B-cell lymphoma. Because of the paucity of large clinical trials, the standard treatment for MZL is still a matter of debate. The purpose of this study was to analyze the role of prognostic markers, treatments, and outcomes in a large cohort of 144 patients with MZL who were diagnosed at our institution between 2003 and 2010. Most of our patients (67%) were diagnosed with extranodal MZL, whereas splenic MZL (11%) was the rarest type. Patient with localized disease received radiotherapy and achieved high response rates (CR, 76%). Like in other indolent lymphomas,19 rituximab has demonstrated effectiveness in the treatment of MZL.20-22 However, a prospective randomized trial on this issue is still missing. In our cohort, among those who chose systemic therapy, 79% of patients with nodal MZL and 87% of patients with extranodal MZL received rituximab with or without chemotherapy. Because of the lack of prospective, randomized studies in MZL, the optimal ...
This open-label, randomized study will compare the efficacy of GDC-0199 plus rituximab (GDC-0199+R) with bendamustine plus MabThera/Rituxan (Rituximab) (B+R) in patients with relapsed or resistant chronic lymphocytic leukemia. Patients will be randomized 1:1 into the two arms. Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2).. Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and bendamustine infusions (70 mg/m2) on Days 1 and 2 of each 28-day cycle.. Patients in the GDC-0199+R arm will continue GDC-0199 treatment until disease progression or 2 years since treatment start, whichever comes first. Anticipated time on study is up to 5 years.. ...
TY - JOUR. T1 - Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP. T2 - Report from an International DLBCL Rituximab-CHOP Consortium Program Study. AU - Xu-Monette, Zijun Y.. AU - Wu, Lin. AU - Visco, Carlo. AU - Tai, Yu Chuan. AU - Tzankov, Alexander. AU - Liu, Wei Min. AU - Montes-Moreno, Santiago. AU - Dybkær, Karen. AU - Chiu, April. AU - Orazi, Attilio. AU - Zu, Youli. AU - Bhagat, Govind. AU - Richards, Kristy L.. AU - Hsi, Eric D.. AU - Zhao, X. Frank. AU - Choi, William W.L.. AU - Zhao, Xiaoying. AU - Van Krieken, J. Han. AU - Huang, Qin. AU - Huh, Jooryung. AU - Ai, Weiyun. AU - Ponzoni, Maurilio. AU - Ferreri, Andrés J.M.. AU - Zhou, Fan. AU - Kahl, Brad S.. AU - Winter, Jane N.. AU - Xu, Wei. AU - Li, Jianyong. AU - Go, Ronald S.. AU - Li, Yong. AU - Piris, Miguel A.. AU - Møller, Michael B.. AU - Miranda, Roberto N.. AU - Abruzzo, Lynne V.. AU - Medeiros, L. Jeffrey. AU - Young, Ken H.. PY - 2012/11/8. Y1 - ...
Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be
Andrew Davies, MD:We can put this information from the blood test, the biopsy, the diagnostic PET [positron emission tomography] scan, and the bone marrow together to look at the scoring system that we use in follicular lymphoma.. For many years weve used the FLIPI score, the Follicular Lymphoma International Prognostic Index, which uses 5 clinical variables. The FLIPI score was created in the era before rituximab and is somewhat difficult to calculate at times, because it does require the assessment of the number of nodal sites involved, which can be a little difficult to calculate. We now have the FLIPI2 score. This is a prospectively evaluative prognostic scoring system that uses 5 clinical variables to help us assign a risk assessment, for which there are 3 different categories for individual patients. They either fall into a high-, intermediate-, or low-risk group, each with distinct progression-free survival and overall survival, and validated in the era of rituximab.. Because this is ...
Incorporating lymphopenia into the Follicular Lymphoma International Prognostic Index (FLIPI) can improve prognostication, according to researchers.
Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkins lymphoma
Maintenance treatment with rituximab after induction immunochemotherapy and HSCT significantly improves survival among young mantle-cell lymphoma
In a recent issue of Arthritis, Research & Therapy, Nakou and colleagues [1] present an interesting study of the effects of rituximab treatment on B cell subsets in both peripheral blood and bone marrow of patients with rheumatoid arthritis (RA). In 2001, Edwards and Cambridge [2] successfully performed the first pilot trial evaluating B cell depletive therapy in five patients with RA. The beneficial effect of treatment with the B cell depleting chimerical antibody rituximab was confirmed in various placebo-controlled clinical trials and approval followed in 2006 in both the EU and US.. The critical role of B cells in the pathogenesis of RA had previously been suggested by the association with auto-antibodies (rheumatoid factor and anti-citrullinated protein antibodies), which can be found already in the preclinical phase of the disease; the presence of lymphocyte aggregates containing B cells, which are often surrounded by large numbers of plasma cells, in the inflamed synovium; and ...
In this study, a retrospective analysis was done to evaluate the influence of TP53 Arg72Pro on the prognosis of 425 Chinese DLBCL patients treated with CHOP or R-CHOP therapy. Patients with genotype GG (Arg/Arg) and GC (Arg/Pro) of SNP rs1042522 had a lower positive rate for β2-MG and higher CR and OR rates for treatment than those with genotype CC (Pro/Pro). In the subgroup treated without rituximab, a significant higher CR rate and higher 5-year OS and PFS rates were achieved in patients with Arg/Arg and Arg/Pro than in those with Pro/Pro. Multivariate analysis revealed TP53 Arg72 as a favorable prognostic factor in this group. As the integration of rituximab in treatment significantly increased the CR, 5-year OS and PFS rates in the subgroup treated with R-CHOP therapy these significant differences vanished between two genotype groups.. The previous study in European Caucasians demonstrated no influence of TP53 Arg72Pro on survival of DLBCL patients [15]. However, we observed better survival ...
Bendamustine and Rituxan (rituximab) is an effective induction regimen for both transplant-eligible and -ineligible patients with mantle cell lymphoma (MCL), with significant improvements in progression-free survival, compared with R-CHOP, according to data published in Blood Advances.. For over two decades, consolidative high-dose chemotherapy and autologous stem cell transplantation (ASCT) have been used in responding young, fit patients given an association with improved progression-free survival (PFS) and overall survival (OS), the authors wrote. Maintenance rituximab after firstline immunochemotherapy, with or without consolidative ASCT, is also associated with improved outcomes, although it is unclear whether the choice of particular firstline immunochemotherapy regimens may influence the effectiveness of (maintenance Rituxan).. The authors noted that between January 2003 and May 2013, Rituxan, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) was the preferred ...
Open in a separate window Table 2. Baseline patients features according to maintenance rituximab. Open in another window With a median follow-up of 11.4 years (range 2.2C14.6) in living sufferers treated with R-CHOP and 7.1 years (range 3.1C10.7) in sufferers treated with R-CHOP-MR, there have been 21 (49%) and 17 (31%) relapses, respectively (DIS ( em P /em =0.274). In the subgroup of sufferers with FL (23 R-CHOP, 44 R-CHOP+MR), the addition of MR didnt influence PFS ( em P /em =0.602), FFP ( em P /em =0.526), or OS ( em P /em =0.771). Open in another window Figure 1. Outcomes according to maintenance rituximab. Progression-free of charge survival: (A) composite lymphoma (COM), (B) discordant lymphoma (DIS); independence from progression: (C) COM, (D) DIS; overall survival: (Electronic) COM, (F) DIS. Age over 60 years was the just variable connected with even worse PFS and FFP in uni- and multivariate analyses. Elevated LDH and poor efficiency status had been associated with even worse FFP in ...
The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) plus rituximab (Rituxan) for the treatment of adult patients with Waldenströms macroglobulinemia (WM). With this approval, the ibrutinib prescribing information now includes combination use with rituximab, representing the first and only chemotherapy-free combination treatment specifically indicated for the disease. Ibrutinib- a first-in-class Brutons tyrosine kinase (BTK) inhibitor-was first approved as a single agent therapy for WM in January 2015.. WM is a rare, slow-growing and incurable form of non-Hodgkin lymphoma with limited treatment options. WM typically affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen also may be affected. In the United States, there are about 2,800 new cases of WM each year.. iNNOVATE Trial. The approval is supported by data from the phase III iNNOVATE trial, which evaluated ibrutinib in combination with rituximab vs rituximab alone in ...
Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkins lymphoma
Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL. Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma (FL) patients. Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma .... ...
WALTHAM, Mass., Nov. 6 /PRNewswire/ -- Decision Resources, one of the worlds leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists anticipate using Bristol-Myers Squibbs Orencia and Biogen Idec/Genentech/ Chugai/Zenyaku Kogyos Rituxan, also marketed as Roches MabThera, more frequently in first- and second-line biologic therapy through 2010 for the treatment of rheumatoid arthritis. Currently, surveyed rheumatologists prescribe Orencia in earlier lines of therapy than Rituxan - 78 percent of them most commonly prescribe Orencia as a third-line biologic, whereas 51 percent of them use Rituxan as a fourth-line biologic, stated Madhuri Borde, Ph.D., analyst at Decision Resources. Surveyed rheumatologists contend that physician familiarity, concern about the long-term effects of B-cell depletion with Rituxan and preference for Orencias mechanism of action influences physicians to prescribe Orencia instead of ...
Following B lymphocyte depletion in patients with RA, a positive clinical response occurred in correlation with a significant drop in the levels of CRP and autoantibodies. Antibacterial antibody levels were relatively well maintained. B lymphocyte return preceded relapse in all patients. There was a …
To undertake a retrospective review of patients with SLE who had received Rituximab in order to determine the rates and associated patient characteristics of clinically significant adverse infusion reactions. A descriptive analysis was undertaken of each infusion reaction, which was then assessed using the clinical information available to hypothesise on the possible underlying mechanism(s). Records of 136 SLE patients previously treated with 481 individual infusions of Rituximab were reviewed. A total of 22 patients (17.6%) had 28 (5.8% of total infusions) documented clinically significant adverse infusion reactions. Average age at first Rituximab infusion in patients without a reaction was 37 years (range 16-73) compared with 30 years (range 18-56) in those with a reaction. A high proportion of men (18.2%) experienced an infusion reaction. Severity and type of reaction varied. 6.4% of those who had a reaction were not retreated. While Rituximab remains an important tool in the treatment of SLE it is
ASPAR PHARMACEUTICALS - We are one of the well known exporter, supplier,Wholesaler and trader of Mabthera Injection. We offer best quality of Mabthera Injection at a best price based in Surat Gujarat, India.
Neutropenia occurred after a median period of 4.5 months (ranging 3-6.5 months), following the last RTX infusion in the RA patients and five months (ranging 3-6.5 months) in OAIDs patients. One RA patient had neutrophils ,500/mm3, seven RA patients had neutrophils between 500 and 1,000/mm3, and 17 RA patients had neutrophils between 1,000 and 1,500/mm3. The OAID patients who developed LON were: seven patients with systemic lupus erythematosus, seven patients with vasculitis and one patient with myositis.. Nineteen patients who developed neutropenia after RTX treatment were retreated with RTX. Of those 19, three developed neutropenia again. No patients developed infections or needed growth factor treatment. In the RA patients who developed LON, no baseline risk factors were identified, except age and female gender. LON in RA occurred, but cases were relatively mild. The authors recommend monitoring blood counts following each cycle of RTX.. ...
Abstract:. Traditional administration of rituximab requires careful titration and may involve many hours to minimize the risk of reactions. The objective of this study was to evaluate the safety of rapid infusions of rituximab in a pilot group of children with hematologic, oncologic, and rheumatologic disorders, and to determine the incidence of rate-related infusion reactions. Twenty patients enrolled in the study. All patients tolerated the rapid infusion of rituximab and no patient had an infusion-related reaction. We conclude that rapid infusions of rituximab are well tolerated and safe in our pilot group of patients.. ...
Significant peripheral blood CD4+ T-cell depletion has been observed after a first cycle of rituximab, a monoclonal antibody directed against the CD20 antigen, which is currently used in rheumatoid arthritis. Of note, an absence of CD4+ T-cell decrease has been observed in non-responders. Herein, we describe CD4+ T-cell changes over repeated cycles of rituximab and their relationship with clinical outcomes.. METHODS ...
MD Anderson News Release 05/31/2011. Landmark study of personalized therapy may lead to a flood of new agents. MD Anderson News Release 05/31/11. A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.. The study continues to show that the vaccine increases the usual time until relapse for follicular lymphoma by about 14 months. Thats significant because most cancer drugs are approved on the basis of extending survival only a few months, said Larry Kwak, M.D., Ph.D., corresponding author of the study. Kwak, who invented the vaccine while at the National Cancer Institute, chairs MD Andersons Department of Lymphoma and Myeloma.. These results have the potential to usher in a new age of cancer vaccines, he said. I ...
The Company reserves the right to modify the Dosing and Frequency Requirements listed in this Policy to ensure consistency with the most recently published recommendations for the use of rituximab infusion or related biosimilars, or rituximab/hyaluronidase human for subcutaneous injection (Rituxan Hycela ). Changes to these guidelines are based on a consensus of information obtained from resources such as, but not limited to: the US Food and Drug Administration (FDA); Company-recognized authoritative pharmacology compendia; or published peer-reviewed clinical research. The professional provider must supply supporting documentation (i.e., published peer-reviewed literature) in order to request coverage for an amount of rituximab infusion or related biosimilars, or rituximab/hyaluronidase human for subcutaneous injection (Rituxan Hycela ) outside of the Dosing and Frequency Requirements listed in this Policy. For a list of Company-recognized pharmacology compendia, view our policy on off-label ...
Those suffering from follicular lymphoma have become accustomed to bone marrow biopsies throughout their treatment so that doctors can monitor their responses.
Other scholarly publications - Abstracts - (continued) 73. Morrison V, Weller E, Haberman TM, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne R, Woda B, Fisher R, Peterson B, Horning SJ: Maintenance rituximab (MR) versus observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL) patients: An intergroup E4494/C9793 update. Proc of the American Society of Clinical Oncology: #8011. (2007). 74. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Chen R, Treat J, Obasaju CK, Schiller JH: Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18s):LBA7516. 75. Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN : A phase II trial of carboplatin and ABI-007 in patients with ...
New draft guidance from the National Institute for Health and Clinical Excellence (NICE) recommends the use of Roches MabThera (rituximab) in combination with a wide range of chemotherapy treatments for symptomatic stage III and IV follicular lymphoma. - News - PharmaTimes
In some HBV carrier cases, there have been reports of HBV reactivation and liver damage occurring during rituximab combination chemotherapy. Recently, with regard to the use of rituximab combination chemotherapy to treat non-Hodgkins lymphoma in people infected with HCV.
Monoclonal human IgG1 antibody against human CD20 Anti-hCD20-hIgG1 features the constant region of the human IgG1 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphoc
... mouse-derived) monoclonal antibody called 3F8. Given intravenously, 3F8 binds specifically to neuroblastoma cells and triggers ... However, its use is limited by the body's eventual development of human anti-murine antibody, which neutralizes the effects. ... "Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors - Full Text View". ... 3 million to fund the genetic engineering of the murine cell line that produces 3F8 so that it would produce a new antibody, ...
... and from (No. ABIN6737444) . Monoclonal antibodies (IgG1) to F-protein are available from Kerafast ( ... PBMC derived T cells activated for 5 days with anti-CD3 antibody and IL-2 also can be used for the purpose. In addition, human ... In need of a reliable method to produce large quantities of a specific antibody, the two merged a monoclonal B cell, exposed to ... Polyclonal antibodies to Sendai virus derived from rabbit are available from MBL international corporation (code pd029) and ...
Using the YP7 murine monoclonal antibody, GPC3 protein expression is found in HCC, not in normal liver and cholangiocarcinoma. ... the antibody-drug conjugates based on hYP7 and the T-cell engaging bispecific antibodies derived from YP7 and GC33, have been ... has generated YP7 and other murine monoclonal antibodies that recognize the C-lobe of GPC3 by hybridoma technology. These ... The YP7 murine antibody has been humanized and named as 'hYP7'. GPC3 is also expressed to a lesser degree in melanoma, ovarian ...
Monoclonal antibody H 9/25 reacts with functional subsets of T and B cells: killer, killer precursor and plaque-forming cells. ... Molecular cloning of murine intercellular adhesion molecule (ICAM-1). The EMBO Journal, 8(10), pp.2889-2896. Takei, F., ... Ly-49-independent natural killer (NK) cell specificity revealed by NK cell clones derived from p53-deficient mice. The Journal ... H9/25 monoclonal antibody recognizes a new allospecificity of mouse lymphocyte subpopulations: Strain and tissue distribution. ...
"Evaluation of lymphatic invasion in primary gastric cancer by a new monoclonal antibody, D2-40". Human Pathology. 37 (9): 1193- ... Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated ... Premalignant Cancer in a Murine Model". The Journal of Immunology. 184 (3): 1543-51. doi:10.4049/jimmunol.0801217. PMID ...
FcγRIV, a murine homologue of CD16A has been shown to be involved in antibody-mediated depletion of tumor-infiltrating ... Margetuximab, an Fc-optimized monoclonal antibody that recognizes the human epidermal growth factor receptor 2 (HER2) expressed ... Several other CD molecules, such as CD11b and CD33, are traditionally used as markers for human myeloid-derived suppressor ... regulatory T cells in monoclonal antibody mediated immunotherapy. Bispecific antibody fragments, such as anti-CD19/CD16, allow ...
A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived ... similar the differences between them were sufficient to invoke an immune response when murine monoclonal antibodies were ... of monoclonal antibodies Monoclonal antibody therapy Nomenclature of monoclonal antibodies Polyclonal antibodies Monoclonal ... Bispecific monoclonal antibodies can also be engineered, by increasing the therapeutic targets of one monoclonal antibody to ...
Blockade of CD47 with a monoclonal antibody results in macrophage engulfment of bladder cancer cells in vitro. CD47 is also ... CD47 also functions as a marker of self on murine red blood cells which allows RBC to avoid phagocytosis. Red blood cells that ... prostate cancer and ovarian cancer-derived cells. In a mouse model of multiple myeloma, tumor metastasis to bone was decreased ... Jurkat cells and peripheral blood mononuclear cells (PBMC) incubated with the monoclonal antibody Ad22 results in apoptosis ...
Anti-OX40 monoclonal antibodies have been shown to have clinical utility in advanced cancer. The pharma company AstraZeneca has ... IDO is known to suppress T and NK cells, generate and activate Tregs and myeloid-derived suppressor cells, and promote tumour ... "LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems". J Clin Invest. 117 ... "CDX-1127 - Monoclonal Antibody Targeting CD27". Celldex Therapeutics. He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, ...
... only the complementarity determining regions of the variable regions are derived from murine sources. Human antibodies have ... Naked monoclonal antibodies are antibodies without added elements. Most antibody therapies use this antibody type. Conjugated ... Chimeric antibodies attempt to reduce murine antibodies' immunogenicity by replacing part of the antibody with the ... Many immunotherapeutic regimens involve antibodies. Monoclonal antibody technology engineers and generates antibodies against ...
... or human anti-murine antibody (HAMA) is an antibody found in humans which reacts to immunoglobins ... These types of antibodies are typically called monoclonal antibodies because they are created to target one specific antigen. ... It has been observed that anywhere from one-third to more than half of patients receiving mouse-derived antibodies will develop ... Monoclonal antibodies can be generated for human use without mice by using in vitro techniques. MAbs manufactured using these ...
Humanised antibodies bind antigen much more weakly than the parent murine monoclonal antibody, with reported decreases in ... "Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques". ... Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind monospecifically to ... To reduce murine antibody immunogenicity (attacks by the immune system against the antibody), murine molecules were engineered ...
Dupilumab is a monoclonal antibody IL-13 and IL-4 modulator that targets the shared receptor of IL-4 and IL-13, IL4Rα. Since IL ... murine studies demonstrated that IL-13 was both necessary and sufficient to generate asthma-like Th2 responses in the mouse ... IL-13Rα2 (which is labelled as a decoy receptor) is derived from Th2 cells and is a pleotropic immune regulatory cytokine. IL- ... a T-cell-derived cytokine that regulates human monocyte and B-cell function". Proceedings of the National Academy of Sciences ...
Monoclonal antibodies targeting the nANGPTL4 and cANGPTL4 have been developed to distinguish their functions. ANGPTL4 plays an ... Murine influenza infection of the lungs stimulated the expression of ANGPTL4 via a STAT3-mediated mechanism. ANGPTL4 enhanced ... ANGPTL4 in nonexercising muscle presumably leads to reduced local uptake of plasma triglyceride-derived fatty acids and their ... June 2019). "Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal ...
Using monoclonal fluorescently labeled antibodies the Frendo Lab was able to visualize the Env-W expression at the apical ... The HERV-W derived element of chromosome 12p11.21 and 7q21.2 had 42 hits from the env gene in pancreatic islet tissues and 224 ... One study found 10 out of 35 individuals with recent onset schizophrenia had retroviral pol gene HERV-W transcripts and murine ... A humanized monoclonal antibody called GNbAc1 of the IgG4 class binds with high specificity and affinity to the extracellular ...
... s are a model cell line derived from the nonsecreting murine myeloma used in biomedical research and commercially in ... Galfrè, G; Milstein, C (1981). "Preparation of monoclonal antibodies: strategies and procedures". Methods in Enzymology. 73 (Pt ... Development of murine neoplasms started with work with the BALB/c mice to isolate the IgG1 secreting MOPC21 tumor. From this ... Several therapeutic antibody products are produced using the NS0 cell line including daclizumab and eculizumab. Barnes, LM; ...
"The production and characterization of murine monoclonal antibodies to a DNA receptor on human leukocytes". Journal of ... These peptides are derived from endogenous cytosolic proteins that are degraded and delivered to the nascent MHC class I ... Antibody responses generated by DNA are useful as a preparative tool. For example, polyclonal and monoclonal antibodies can be ... Antibody-secreting cells migrate to the bone marrow and spleen for long-term antibody production, and generally localise there ...
... pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies". Nucleic Acids Res. 19 (3 ... Akhurst RJ, Lehnert SA, Faissner A, Duffie E (1990). "TGF beta in murine morphogenetic processes: the early embryo and ... Rettig WJ, Triche TJ, Garin-Chesa P (1989). "Stimulation of human neuronectin secretion by brain-derived growth factors". Brain ... Also, tenascin-C antibodies have been used to diagnose and create therapies for many different types of cancers. Tenascin ...
"Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys". Journal ... Humans with inactivating glucagon mutations (i.e. Mahvash disease) and several murine models of reactive alpha cell hyperplasia ... "Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet alpha-cells but not of ... "Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides". PLoS One. 10 (7): e0133812. Bibcode: ...
Krolick KA, Uhr JW, Slavin S, Vitetta ES (Jun 1982). "In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A ... Herman Waldmann, Slavin was the first to introduce the use of an anti-CD52 monoclonal antibody (CAMPATH-1; Alemtuzumab and ... Apr 2019). "Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward mylein as a platform ... Initially, Slavin pioneered the use of monoclonal antibodies anti-CD52 (Alemtuzumab, now approved by FDA as Lemtrada) for ...
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. „Cancer Res". 59 (13 ... bone marrow-derived dendritic cells decreases inhibitory and regulatory T cell differentiation and improves survival in murine ... thymus-derived Treg cells);. *indukowane (adoptywne) limfocyty Treg (iTreg lub aTreg) - komórki Treg powstające w tkankach ... periphery derived Treg cells).. Należy zwrócić uwagę na fakt, że limfocyty Treg uzyskiwane w sposób sztuczny (w warunkach in ...
November 2005). "Molecular characterization of a neutralizing murine monoclonal antibody against Tityus serrulatus scorpion ... These antivenoms are obtained by the immunisation of horses with a mix of venoms derived from T.Serrulatus and T.Bahiensis. ...
... preventing this therapy from being used in combination with monoclonal antibody therapies. NK-92 cells were derived from a ... In mice, the majority of research was carried out with murine cytomegalovirus (MCMV) and in models of hapten-hypersensitivity ... To determine the ADCC contribution of monoclonal antibodies, NK-92 cells (a "pure" NK cell line) has been transfected with the ... This is a major killing mechanism of some monoclonal antibodies like rituximab (Rituxan), ofatumumab (Azzera), and others. The ...
1985). "A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B, non-T lymphoblasts in acute leukaemia and CGL ... CD34 derives its name from the cluster of differentiation protocol that identifies cell surface antigens. CD34 was first ... Ogawa M, Tajima F, Ito T, Sato T, Laver JH, Deguchi T (Jun 2001). "CD34 expression by murine haematopoietic stem cells. ... A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells". Journal of ...
Scolnick EM, Papageoege AG, Shih TY (1979). "Guanine nucleotide-binding activity for src protein of rat-derived murine sarcoma ... updated the labels of two anti-EGFR monoclonal antibody drugs indicated for treatment of metastatic colorectal cancer, ... The viral oncogene was derived from cellular genome. Thus, KRAS gene in cellular genome is called a proto-oncogene. The gene ... "Nucleotide sequence of the oncogene encoding p21 transforming protein of Kirsten murine sarcoma virus". Science. 217 (4563): ...
The use of monoclonal antibodies for therapy is now widespread for treatment of cancers and inflammatory diseases. Using ... Cellulose sulphate is derived from cotton and, once processed appropriately, can be used as a biocompatible base in which to ... In 1998, a murine model of pancreatic cancer was used to study the effect of implanting genetically modified cytochrome P450 ... "Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies". Human Gene Therapy. 11 (10): 1407 ...
... discrimination from splenin by monoclonal antibodies". Archives of Biochemistry and Biophysics. 228 (1): 292-8. doi:10.1016/ ... TMPO beta is a human homolog of the murine protein LAP2. LAP2 plays a role in the regulation of nuclear architecture by binding ... "Three distinct human thymopoietins are derived from alternatively spliced mRNAs". Proceedings of the National Academy of ...
Some of the common monoclonal antibodies used to detect this protein are clones OX7, 5E10, K117 and L127. There have been some ... It is probably the most abundant glycoprotein of murine thymocytes, with about One million copies per cell covering up to 10-20 ... and fetal liver-derived hemopoietic cells. Thy-1 is present on a fraction of brain cells and a fraction of fibroblasts of most ... Single tail vein intravenous injection of antibody (OX7 mouse monoclonal IgG) against Thy1.1 in rats is used as a standard ...
1985). "A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B, non-T lymphoblasts in acute leukaemia and CGL ... CD34 is expressed in roughly 20% of murine hematopoietic stem cells,[21] and can be stimulated and reversed.[22] ... Bellini A, Mattoli S (Sep 2007). "The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and ... A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells". Journal of ...
... of human clonogenic osteoblast progenitors immunoselected from fetal bone marrow stroma using STRO-1 monoclonal antibody". ... Adipose tissue-derived MSCs (AdMSCs), in addition to being easier and safer to isolate than bone marrow-derived MSCs, can be ... April 2011). "Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function ... Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells". Stem Cells and Development ...
3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models". Journal of Immunology. ... One of the most common sources of β(1,3)D-glucan for supplement use is derived from the cell wall of baker's yeast ( ...
Antibodies. *Antibody *Monoclonal antibodies. *Polyclonal antibodies. *Autoantibody. *Microantibody. *Polyclonal B cell ... Granulocytes are derived from stem cells residing in the bone marrow. The differentiation of these stem cells from pluripotent ... "Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages". Journal of ... Toxic oxygen-derived products (e.g., superoxide, hydrogen peroxide, hydroxy radicals, singlet oxygen, hypohalite) ...
Stiff man human cerebellum stained with a reference anti-GAD65 monoclonal antibody. Thin arrows show presynaptic terminals ... "Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes". Nature. 366 (6450): ... Antibodies directed against glutamic acid decarboxylase (GAD) are increasingly found in patients with other symptoms indicative ... The pattern of anti-GAD antibodies in epilepsy differs from type 1 diabetes and stiff-person syndrome.[33] ...
Chuntharapai A, Lee J, Hébert CA, Kim KJ (1994). "Monoclonal antibodies detect different distribution patterns of IL-8 receptor ... CXCR1 can be cleaved and inactivated by Neutrophil Derived Serine Proteases (NSPs), leading to neutrophil dysfunction and ... "Functional and receptor binding characterization of recombinant murine macrophage inflammatory protein 2: sequence analysis ... and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human ...
"Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia". Infect. Immun. 77 (7): ... Although the lytic activity of some microbe-derived hemolysins on red blood cells may be of great importance for nutrient ... "Staphylococcus aureus α-hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 ... At the moment, apiegnin and beta-cyclodextrin are thought to alleviate S.aureus pneumonia, whereas the antibodies of anti alpha ...
Nicolas JF, Reano A, Kaiserlian D, Thivolet J.,Epithelial cell heterogeneity in mammalian thymus: monoclonal antibody to high ... Laila Yousef AL-Ayadhi ja Gehan Ahmed Mostafa, Elevated serum levels of macrophage-derived chemokine and thymus and activation- ... Lymphoepithelial cell complexes in murine thymuses: morphological and serological characterization., J Exp Med. 1. aprill 1980; ... A unique thymic fibroblast population revealed by the monoclonal antibody MTS-15., J Immunol. 15. aprill 2007;178(8):4956-65., ...
A study called BLISS-76 tested the drug belimumab, a fully human monoclonal anti-BAFF (or anti-BLyS) antibody.[85] BAFF ... Cells derived from SLE patients are unable to repair DNA damages as efficiently as control cells, and it has been suggested ... and murine studies.[50] Further genetic studies of multiple ethnic groups and the creation of disease models incorporating ... Subtypes of antinuclear antibodies include anti-Smith and anti-double stranded DNA (dsDNA) antibodies (which are linked to SLE ...
Attempts have been made to outfit microbubbles with monoclonal antibodies that bind P-selectin, ICAM-1, and VCAM-1,[4] but the ... Targeting ligands can be immunogenic, since current targeting ligands used in preclinical experiments are derived from animal ... Pre-clinical in vivo Validation in a Murine Tumor Model". Abstracts of the 2013 World Molecular Imaging Congress. Savannah, USA ... Currently, these ligands are monoclonal antibodies produced from animal cell cultures that bind specifically to receptors and ...
This is a major killing mechanism of some monoclonal antibodies like rituximab (Rituxan), ofatumumab (Azzera), and others. The ... Expression of HLA-E at the cell surface is dependent on the presence of nonamer peptide epitope derived from the signal ... and uterine natural killer cell maturation during normal murine pregnancy". The Journal of Experimental Medicine. 192 (2): 259- ... To determine the ADCC contribution of monoclonal antibodies, NK-92 cells (a "pure" NK cell line) has been transfected with the ...
Seth Lederman at Columbia University generated an murine monoclonal antibody, 5c8 that inhibited contact-dependent T cell ... Of note, recent studies suggest that only ~5% of the lymphoid-derived CD4 T cells targeted by HIV are permissive and become ... Stimulates B-cells into proliferation, to induce B-cell antibody class switching, and to increase neutralizing antibody ... Randolph Noelle at Dartmouth Medical School generated an antibody that bound a 39 kDa protein on murine T cells and inhibited ...
Lee JS, Burkholder GD, Latimer LJ, Haug BL, Braun RP (February 1987). "A monoclonal antibody to triplex DNA binds to eucaryotic ... Lin R, Maeda S, Liu C, Karin M, Edgington TS (February 2007). "A large noncoding RNA is a marker for murine hepatocellular ... The RNAP III transcribed BC1 and BC200 ncRNAs, that previously derived from tRNAs, are expressed in the mouse and human central ... Families of transposable elements-derived lincRNAs have been implicated in the regulation of pluripotency. Human pluripotency- ...
A last-resort treatment in those who are immunosuppressed is intravenous immunoglobulin.[72] Monoclonal antibodies against C. ... increases post-treatment survival and improves clinical measures of disease in a murine model". The Journal of Antimicrobial ... human-derived fecal matter is difficult to standardize and has multiple potential risks, including the transfer of infectious ... CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1) is an investigational, monoclonal antibody combination ...
Magnani, DM; Rogers TF, Beutler N, Ricciardi MJ; et al «Neutralizing human monoclonal antibodies prevent Zika virus infection ... Dins del context d'una infecció murina controlada, aquestes troballes suggereixen que la patologia placentària podria ser el ... Inactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma-derived products and pasteurization ... Koma T, Veljkovic V, Anderson DE, Wang LF, et al «Zika virus infection elicits auto-antibodies to C1q» (en anglès). Sci Rep, ...
... as well a potential monoclonal antibody against HGF and c-Met. ... "Olive-Oil-Derived Oleocanthal Enhances β-Amyloid Clearance as ... "Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell ... Naturally Occurring Non-steroidal Anti-inflammatory and Anti-oxidant Agent Derived from Extra Virgin Olive Oils". Organic ... "Olive Oil-derived Oleocanthal as Potent Inhibitor of Mammalian Target of Rapamycin: Biological Evaluation and Molecular ...
Xia C, Ribeiro M, Scott S, Lonial S (October 2016). "Daratumumab: monoclonal antibody therapy to treat multiple myeloma". Drugs ... Feito MJ, Bragardo M, Buonfiglio D, Bonissoni S, Bottarel F, Malavasi F, Dianzani U (August 1997). "gp 120s derived from four ... extensive structural homology with the genes for murine bone marrow stromal cell antigen 1 and aplysian ADP-ribosyl cyclase". ... Thus, a screening assay for irregular antibodies against red blood cell antigens or a direct immunoglobulin test can produce ...
PCR facilitated by a neutralizing monoclonal antibody directed against Taq DNA polymerase". BioTechniques. 16 (6): 1134-7. PMID ... Park DJ (2005). "A new 5' terminal murine GAPDH exon identified using 5'RACE LaNe". Molecular Biotechnology. 29 (1): 39-46. doi ... Solid Phase PCR: encompasses multiple meanings, including Polony Amplification (where PCR colonies are derived in a gel matrix ... However, antibodies don't appear until many weeks after infection, maternal antibodies mask the infection of a newborn, and ...
APC-derived cytokines and T cell polarization in autoimmune inflammation. The Journal of Clinical Investigation. 2007-05, 117 ( ... Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine ... Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. ... in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies ...
Antibodies. *Antibody *Monoclonal antibodies. *Polyclonal antibodies. *Autoantibody. *Microantibody. *Polyclonal B cell ... Some murine γδ T cells recognize MHC class IB molecules, though. Human Vγ9/Vδ2 T cells, which constitute the major γδ T cell ... "T cells and B cells derive their names from the organs in which they develop. T cells develop in the thymus, and B cells, in ... The ability of T cells to ignore healthy cells but respond when these same cells contain pathogen (or cancer) derived pMHC is ...
Their structure is derived from morpholino pyrazolopyrimidine scaffold.[20][22] Improvements of this type of inhibitors have ... Recently rapamycin has shown effective in the inhibition of growth of several human cancers and murine cell lines.[5] Rapamycin ... Antibodies. Monoclonal. Serum target. (noncellular). *Complement component 5 *Eculizumab. *TNF *Adalimumab. *Afelimomab ... from where its name is derived.[4] Rapamycin is a macrolide, produced by the microorganism Streptomyces hygroscopicus and ...
also identified Ten-m in Drosophila by screening for tyrosine phosphorylation on cDNA using monoclonal antibodies. However, ... Zhou XH, Brandau O, Feng K, Oohashi T, Ninomiya Y, Rauch U, Fässler R (August 2003). "The murine Ten-m/Odz genes show distinct ... The embryonic Drosophila cDNA library was screened using polymerase chain reaction (PCR) and a primer derived from the EGF-like ...
Controversy regarding ERβ protein expression has hindered study of ERβ, but highly sensitive monoclonal antibodies have been ... Thus, ERβ helps control Aβ levels by maintaining the protein it is derived from, β-amyloid precursor protein. ERβ helps by up- ... Vidal O, Kindblom LG, Ohlsson C (June 1999). "Expression and localization of estrogen receptor-beta in murine and human bone". ... "Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its ...
"Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody". The Journal of Neuroscience. 17 (1): 23-31. ... García-Moreno F, López-Mascaraque L, De Carlos JA (January 2007). "Origins and migratory routes of murine Cajal-Retzius cells ... Borrell V, Marín O (October 2006). "Meninges control tangential migration of hem-derived Cajal-Retzius cells via CXCL12/CXCR4 ... Soriano E, Del Río JA, Martínez A, Supèr H (April 1994). "Organization of the embryonic and early postnatal murine hippocampus ...
PCR facilitated by a neutralizing monoclonal antibody directed against Taq DNA polymerase". BioTechniques. 16 (6): 1134-7. PMID ... Solid Phase PCR: encompasses multiple meanings, including Polony Amplification (where PCR colonies are derived in a gel matrix ... terminal murine GAPDH exon identified using 5'RACE LaNe". Molecular Biotechnology. 29 (1): 39-46. doi:10.1385/MB:29:1:39. PMID ... However, antibodies don't appear until many weeks after infection, maternal antibodies mask the infection of a newborn, and ...
ALDH alkaline phosphatase alpha6-integrin Anti-WNT2B monoclonal antibody antithrombin III (AT) asialo GM1 Bcl-2 Beta- ... Kues WA, Petersen B, Mysegades W, Carnwath JW, Niemann H (April 2005). "Isolation of murine and porcine fetal stem cells from ... December 2006). "Neural crest-derived cells with stem cell features can be traced back to multiple lineages in the adult skin ... June 2001). "Expression of anti-OV6 antibody and anti-N-CAM antibody along the biliary line of normal and diseased human livers ...
Antibodies, Monoclonal / immunology * Antibodies, Monoclonal / therapeutic use* * Antibodies, Monoclonal, Murine-Derived * ... A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian ... Immune responses, including antibodies and T cells to oregovomab and CA125, were demonstrated in over half the patients. ...
Crystal structure of the Fab fragment of 9E5, a murine monoclonal antibody specific for human epiregulin. *DOI: 10.2210/pdb5AZ2 ... The 9E5 antibody will also be useful in medicine as a neutralizing antibody specific for colon cancer. ... anti-human epiregulin antibody 9E5 Fab heavy chain. H. 222. Mus musculus. Mutation(s): 0 ... anti-human epiregulin antibody 9E5 Fab light chain. L. 213. Mus musculus. Mutation(s): 0 ...
... and generated a panel of hybridoma cell clones secreting IgA class monoclonal antibodies. A total of 12 neutralizing IgA MAbs ... All neutralization-escape variants selected by this antibody group contained mutations at amino acids 132- 135 of VP4. One IgA ... To better understand the localization of viral epitopes involved in antibody-mediated neutralization of virus infectivity, we ... Characterization of neuraminidase-resistant mutants derived from rotavirus porcine strain OSU.. José A. López, Antonio José ...
Antibodies, Monoclonal, Murine-Derived/chemistry*. *Antibodies, Monoclonal, Murine-Derived/immunology. *Antibody Affinity* ... Characterization of monoclonal antibodys binding kinetics using oblique-incidence reflectivity difference approach.. Liu S1, ... Monoclonal antibodies (mAbs) against human proteins are the primary protein capture reagents for basic research, diagnosis, and ... Characterization of monoclonal antibodys binding kinetics using oblique-incidence reflectivity difference approach ...
serum-derived human monoclonal IgM;. TMEV,. Theilers murine encephalomyelitis virus. *Received December 27, 1999. ... Our sources of human mAbs were serum-derived human monoclonal IgMs (sHIgMs) and sera-derived human monoclonal IgGs (sHIgGs). ... Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Arthur E. ... Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis ...
Antibodies, Monoclonal, Murine-Derived / therapeutic use* * Antirheumatic Agents / therapeutic use* * Female * Humans ...
Using a murine model of demyelination induced by a gliatropic coronavirus, in which BMDM are redundant for demyelination, we ... Using a murine model of demyelination induced by a gliatropic coronavirus, in which BMDM are redundant for demyelination, we ... The CD4 T cell-induced autoimmune murine model of MS, experimental autoimmune encephalitis (EAE), in which BMDM are essential ... The CD4 T cell induced autoimmune murine model of MS, experimental autoimmune encephalitis (EAE), in which BMDM are essential ...
... platelet-derived growth factor receptor; FGFR, fibroblast growth factor receptor; TC, tumor cell; mAb, monoclonal antibody; PE ... On day 7, when tumors reach ∼0.5 cm in diameter, mice were inoculated s.c. with murine recombinant B7.2-IgG fusion protein (100 ... Treatments with anti-CD4 or anti-CD8 antibody were repeated 2 days after vaccination. Similar injections of antibodies were ... 4T1/IAd/B7.1 subline was derived from 4T1 cells cotransfected with the MHC class II H-2Ad and B7.1 genes (19 , 20) . Both lines ...
We therefore also analyzed the cross-reactivity of monoclonal antibodies derived from hybridomas. This permitted an assessment ... Monoclonal antibodies were secreted by the transferred B cells in splenic fragment cultures. These antibodies were evaluated ... Natural murine autoantibodies and conventional antibodies exhibit similar degrees of antigenic cross-reactivity.. D M Klinman, ... The autoantibodies and conventional antibodies produced in splenic fragment cultures by normal DBA/2 and autoimmune NZB B cells ...
Antibodies, Monoclonal, Murine-Derived. *Liver Cancer. *Single Nucleotide Polymorphism. *Introns. *Thyroid Cancer ... The role of αv integrin on gastrin-induced cell adhesion was examined using blocking anti-αv integrin monoclonal antibodies. ... The use of blocking anti-αv integrin monoclonal antibodies completely reversed the increase in cell-substrate adhesion induced ... BACKGROUND: Administration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor ...
0 (Antibodies, Monoclonal, Murine-Derived); 0 (Capsid Proteins); 0 (Hepatitis Antibodies). [Em] M s de entrada:. 1711. ... and the treated particles became accessible with an anti-HEV ORF2 monoclonal antibody (MAb). The HEV particles in the exosome ... Anticorpos Monoclonais Murinos/farmacologia. Linhagem Celular. Exossomos/metabolismo. Anticorpos Anti-Hepatite/farmacologia. ... Purified CD63-, CD9-, or CD81-positive exosomes derived from the culture supernatants of HEV-infected cells that had been ...
0 (AIDS Vaccines); 0 (Antibodies, Monoclonal, Murine-Derived); 0 (Antibodies, Neutralizing); 0 (HIV Antibodies); 0 (HIV ... Each of the 852 mutants was expressed in human cells and screened for antigenicity using four different monoclonal antibodies ( ... Anticuerpos Monoclonales de Origen Murino/inmunolog a. Anticuerpos Neutralizantes/inmunolog a. C lulas HEK293. Anticuerpos Anti ... The parental protein target, the clade B strain B41 SOSIP.664 gp140, does not bind the broadly neutralizing antibody PGT151 and ...
Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived / therapeutic use. B-Lymphocytes / drug ... 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Murine-Derived; 0/hLL2 agent; 0/rituximab ... will include 100 patients having anti-Ro/La antibodies, reduced basal secretion but an increased salivary flow with stimulation ...
Advances in technology have enabled monoclonal antibodies to be produced which bind to specific antigens associated with ... Murine. Wholly mouse derived antibody -omab edrecolomab Chimeric. Murine antigen binding site; human Fc portion -ximab infli ... The first monoclonal antibodies were mouse derived and anti-mouse antibodies were common although they only occasionally caused ... factors associated with the monoclonal antibody itself (specificity, avidity and isotype). Monoclonal antibodies work by a ...
Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has ... been modified to produce such antibodies in response to antigenic challe ... This compares very favorably with the affinities of murine monoclonal antibodies derived from normal mice. TABLE 4 ... Kinetic constants of fully human monoclonal antibodies (lgG2, kappa) derived from XenoMouse ™ II-a with specificity to human IL ...
Novimmune is a humanized counterpart of rat anti-TLR4 monoclonal antibody; 1A6, found to reduce inflammation in a murine ... Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest ... A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J ... Signal transduction pathway in the murine macrophage-like cell line RAW264.7. J Surg Res (2012) 175(1):88-100. doi:10.1016/j. ...
Antibodies, Monoclonal, Murine-Derived (therapeutic use) *Autoantibodies (blood) *B-Lymphocytes (drug effects) ... Rituximab (RTX), a monoclonal antibody to CD20, leads to B lymphocyte depletion and has been used in some autoimmune disorders ... Patients were monitored by serial clinical assessments, flow cytometry of peripheral blood B lymphocytes and antibody testing. ... or muscle specific kinase antibody (MuSK) positive myasthenia gravis (three subjects), who had been treated with RTX in ...
Antibodies, Monoclonal, Murine-Derived (therapeutic use) *Antineoplastic Combined Chemotherapy Protocols (therapeutic use) ...
... and IgA antibodies in high purity were obtained after purification. The monoclonal IgA antibodies possessed a high sialylation ... Therefore, for patients who do not sufficiently benefit from therapeutic IgG antibodies, IgA antibodies may complement current ... which can at least in part be attributed to the more complex glycosylation as compared to IgG antibodies. IgA antibodies ... The IgA antibodies exhibited potent Fab- and Fc-mediated functionalities against cancer cell lines, whereby especially ...
... consistent with enhanced cross-presentation of tumor-derived antigen. Monoclonal antibodies should be tested as vaccine ... Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine ... Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine ... Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine ...
... monoclonal antibody).. *Have a known allergy to murine proteins or other chimeric proteins. ... Have shown a previous immediate hypersensitivity response, including anaphylaxis, to an immunoglobulin product (plasma-derived ... HIV antibody positive.. *Previous Infliximab or other anti-TNF treatment, previous interferon; Pegylated interferon alfa-2b and ...
Gal-1 antibody (0.1 μg/ml, R&D system, MN, USA); galectin-3 antibody (0.1 μg/ml, R&D system, MN, USA); a monoclonal rabbit ... a novel calixarene derived from anginex, binds to Gal-1 specifically on the side back face [18]. Recent work indicated that ... a monoclonal rabbit antibody against VEGFR2 (rabbit mAb, 1 : 500, Cell Signaling Technology, MA, USA); a monoclonal rabbit ... antibody against pVEGFR2 (pVEGFR2 rabbit mAb, 1 : 500, Cell Signaling Technology, MA, USA); and a monoclonal rabbit antibody ...
Monoclonal antibody 1D8 (ATCC VR-1642) reacts specifically with influenza A virus H9 hemagglutinin by ELISA against recombinant ... Monoclonal antibody 1D8 Application: 1D8 is useful for western blotting and ELISA applications. ... This product is a murine monoclonal antibody (IgG1; kappa light chain) to the HA1 domain of the H9 hemagglutinin of an avian ... The source hybridoma was derived by immunization of a BALB/c mouse, followed by fusion of splenocytes from the immunized animal ...
Some studies showed promising results in the treatment of synovial sarcoma xenografts with a murine monoclonal antibody. [27] ... An additional innovative technique could be an SYT-SSX-derived peptide vaccine. [9] ... Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008 Feb. 99(2):432-40. [ ... Clinical applications of these monoclonal antibodies are not yet available. ...
Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol Pharmacol 55: 614-624, 1999. ... Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Michael Romio, Benjamin ... Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells ... Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells ...
... specific cytotoxic IgM monoclonal antibodies (McAbs), B6-1 and B6-2, were isolated from C57B1/6 (B6) mice after injections of ... Katz, D.H. Skidmore B.J., Katz, L.R., and Bogowitz C.A.: Adaptive differentation of murine lymphocytes. I. Both T and B ... parental chimeras manifest preferential cooperative activity for partner lymphocytes derived from the same parental type ... Monoclonal H-2 Class I Specific Antibodies Isolated After Immunization of C57B1/6 Mice with Syngeneic Sendai Virus-Coated Cells ...
... such as chimeric monoclonal antibodies that consist of murine-derived antigen-binding fragment (Fab) and human-derived ... Biologic agents - Chimeric monoclonal antibodies, humanized monoclonal antibodies, human monoclonal antibodies used in the ... Humanized antibody contains murine-derived, antibody-binding portion integrated into human antibodies by recombinant ... However, the use of equine and murine antisera as antilymphocyte or antithymocyte globulins and murine monoclonal antibodies ...
Antibodies, Monoclonal, Murine-Derived/pharmacology*. *Aqueous Humor/drug effects*/metabolism*. *Interleukin-10/metabolism* ...
Fremanezumab is a humanised IgG2Δa/kappa monoclonal antibody derived from a murine precursor. Fremanezumab selectively binds ... Since monoclonal antibodies are not known to be eliminated via renal pathways or metabolised in the liver, renal and hepatic ... Similar to other monoclonal antibodies, fremanezumab is expected to be degraded by enzymatic proteolysis into small peptides ... Fremanezumab is a humanised monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. ...
Mouse (Murine) Monoclonal PDGFRA Primary Antibody für Func, IHC (f) - ABIN967626 : Fruttiger, Calver, Krüger, Mudhar, ... Monoclonal PDGFRA Primary Antibody für FACS - ABIN1176995 : Heldin: Structural and functional studies on platelet-derived ... Mouse (Murine) Platelet-Derived Growth Factor Receptor, alpha Polypeptide (PDGFRA) Interaktionspartner * Spreading of PDGFR- ... alpha-type platelet-derived growth factor receptor , platelet-derived growth factor alpha receptor , platelet-derived growth ...
  • TA99 is an IgG2a murine antibody directed against tyrosinase-related protein-1 (Tyrp1), of identical specificity to an antibody isolated from the serum of a melanoma patient ( 10 ). (
  • Sensitivity, specificity, and likelihood ratio are reported for discrete threshold values of IL-10 (Table 5), IL-6 (Table 6), and IL-10/IL-6 (Table 7) as derived by GraphPad Prism. (
  • Three IgG1 human monoclonal antibodies (HMAbs) were purified and their binding specificity to E protein was verified by ELISA and biolayer interferometry. (
  • Traditional CARs have been generated using single-chain variable fragments (scFv), often derived from murine monoclonal antibodies, for antigen specificity. (
  • These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. (
  • In addition, only PrP res from H-type isolates were labeled by monoclonal antibody P4 with defined PrP res N terminus epitope specificity, in contrast with PrP res from BSE isolates, which suggests a different cleavage by proteinase K of the disease-associated protein ( 9 ). (
  • The complementarity determining region (CDR) of an antibody or a T lymphocyte receptor determines its specificity and is the point of contact with a specific ligand. (
  • Therefore, an ADCC assay involves three essential components: labeled target cells, antibodies with specificity for target‐cell surface antigens, and effector‐cell populations. (
  • The specificity of antibodies is determined by the amino acid sequence on the tips of the Y shape. (
  • One of the greatest challenges in biomedical research on antibodies is to mimic the screening process of the human immune system as closely as possible in order to identify antibodies with the highest target/antigen specificity (3). (
  • Rituximab (RTX), a monoclonal antibody to CD20, leads to B lymphocyte depletion and has been used in some autoimmune disorders, including small case series of myasthenia gravis patients. (
  • RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. (
  • PDF] Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus. (
  • These antibodies were evaluated for reactivity and cross-reactivity against a panel of six autoantigens and two conventional antigens using an ELISA assay. (
  • Consistent with our earlier observations, hybridoma antibodies specific for conventional antigens exhibited cross-reactivity with a frequency similar to that of antibodies specific for autoantigens. (
  • Advances in technology have enabled monoclonal antibodies to be produced which bind to specific antigens associated with disease processes. (
  • By targeting these antigens the antibodies can destroy or alter the function of cells which express the target. (
  • One strategy to improve T cell-based immunotherapy is to combine it with antibodies targeting antigens relevant to a specific tumor type ( 4 , 5 ). (
  • Two-site immunometric assays for multideterminant antigens are described in which the antigen is reacted with an immobilized monoclonal antibody directed against one antigen determinant and a second monoclonal antibody that is directed against a distinct antigenic determinant and is of a different class. (
  • 1. A monoclonal antibody produced by hybridoma cell line 7E11-C5, ATCC Designation HB 10494, which monoclonal antibody binds specifically to an epitope present on a membrane associated antigen of human prostatic cancer epithelium and normal prostatic epithelium and which does not bind to non-prostatic antigens present in other tissues. (
  • This invention relates to the production of and applications for monoclonal antibodies specific for prostatic tumor antigens. (
  • Monoclonal antibodies capable of reacting with membrane associated surface antigens are of value for the immuno-classification and detection of disease and represent novel agents for immunotherapy. (
  • The most prominent passive immunotherapies, which have revolutionized cancer therapy, are monoclonal antibodies that either target tumor-specific antigens and receptors or block important pathways central to tumor growth and survival. (
  • Therapeutic antibodies target and bind to antigens, usually proteins that are mainly expressed on diseased cells such as cancer cells. (
  • The therapeutic efficacy of combined antiangiogenic and immune therapy was tested against weakly immunogenic and highly metastatic 4T1 breast tumor using SU6668, an angiogenesis inhibitor and recombinant murine (rm) B7.2-IgG fusion protein, an immunostimulator. (
  • Therefore, for patients who do not sufficiently benefit from therapeutic IgG antibodies, IgA antibodies may complement current regiment options and represent a promising strategy for cancer immunotherapy. (
  • Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. (
  • One key issue with regard to the therapeutic use of monoclonal antibodies has been the response of the human immune system to xenogeneic antibodies. (
  • Furthermore, PI3Kδi imparted significant therapeutic responses in Eμ-Tcl1-bearing animals and enhanced anti-CD20 monoclonal antibody therapy. (
  • The identifications of therapeutic antibodies often requires several rounds of further development and fine-tuning. (
  • However, current methods and technologies can accelerate antibody optimisation to generate superior therapeutic and diagnostic candidates. (
  • Muromonab, the first therapeutic mAb that received approval by the US Food and Drug Administration (FDA) in 1986, was derived from murine hybridoma. (
  • Mouse mAbs often cause a reaction called human anti-mouse response (HAMA) where the patient s immune system recognises these therapeutic antibodies as foreign and causes an immune response. (
  • Besides these problematic and undesirable immune responses to therapeutic antibodies that can neutralise their effect, mouse-derived mAbs can also cause serious adverse events, such as hypersensitivity. (
  • Additionally, therapeutic antibodies have to be safe in humans and must have the ability to be manufactured on a large scale. (
  • Although very successful, especially in oncology, therapeutic antibodies have a significant limitation: they don't generate a memory response by the immune system, and thus, repeated antibody infusions are required. (
  • As a result of successful experiments in experimental autoimmune encephalomyelitis (EAE) models on both clinical and MRI outcomes, 3 - 5 it was proposed that antibodies against α4β1 integrin may have therapeutic value in MS, both as a potential treatment of acute exacerbations of the disease and to inhibit the occurrence of subsequent attacks. (
  • Monoclonal antibodies (mAbs) against human proteins are the primary protein capture reagents for basic research, diagnosis, and molecular therapeutics. (
  • Human mAbs were isolated from the sera of individuals with a form of monoclonal gammopathy. (
  • These individuals carry a high level of monoclonal protein in their blood without detriment, lending support to the belief that administration of these mAbs as a therapy would be safe. (
  • We undertook a novel approach by generating high-affinity human monoclonal antibodies (mAbs) to the human glucagon receptor (GCGR) that display potent antagonistic activity in vitro and in vivo. (
  • There are currently 17 monoclonal antibodies (mAbs) approved by the FDA in the US. (
  • To circumvent these problems, the next generation of antibodies were chimeric mAbs mouse-human antibodies made up of two-thirds human sequence homology followed by humanised mAbs, which have 95 per cent human sequence homology. (
  • Today, several human mAbs have been approved in the US and they account for the majority of antibodies in clinical development. (
  • The complete elimination of murine-derived protein structures will lead to less immunogenic mAbs as compared to humanised or chimeric mAbs. (
  • The constant region (Fc domain) at the stem of the antibody can have only a limited number of forms, and plays a role in modulating the effector function of an antibody, which usually requires the prior binding of an antigen.Manipulations in the Fc regions can influence the pharmacokinetic properties of mAbs as well as improve the antibodydependent cellular cytotoxicity (ADCC). (
  • We generated five influenza virus hemagglutinin (HA)-reactive human monoclonal antibodies (MAbs) by hybridoma technology from the peripheral blood of healthy donors who were born between 1950 and 1968. (
  • MAbs 8M2 and 2G1 shared the V H 1-69 germ line gene, but these antibodies were otherwise not genetically related. (
  • rmB7.2-IgG is a fusion protein of the extracellular domain of B7.2, and the hinge and constant domains of murine IgG2a. (
  • Shortly after the administration of the foreign protein, the host mounts a specific antibody response to clear the foreign substance. (
  • 3. The immunoassay of claim 1 wherein the immobilized monoclonal antibody is immobilized by Protein A. (
  • The immunoassay of claim 6 wherein after (b) and before (c) the protein A complexes are separated from the incubation mixture of (b) and washed with an aqueous medium having a pH that selectively removes nonspecifically bound second monoclonal antibody from the protein A complexes. (
  • B cell cultures were screened by ELISA for antibodies to dengue (DENV) envelope (E) protein. (
  • The E protein is the primary target for antibody-mediated neutralization and thus the focus of vaccine design. (
  • These results provide the protein characterization required for the analysis of the mobility of Antibody MVS-1 bound to the plasma membrane of SB-1 cells. (
  • Antibodies targeting citrullinated proteins (ACPAs [anticitrullinated protein antibodies]) are commonly found in patients with rheumatoid arthritis (RA), strongly associate with distinct HLA-DR alleles, and predict a more aggressive disease course as compared with seronegative patients. (
  • The antibody is specific for a 25-kDa protein component (T3-epsilon) of the antigen-specific T-cell receptor. (
  • Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). (
  • The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen. (
  • Immature DCs derived from CD34 � HPCs migrate most vigorously in response to macrophage inflammatory protein (MIP)-3�, but also to MIP-1 � and RANTES (regulated on activation, normal T cell expressed and secreted). (
  • iii) rVVs encoding peptide V minigenes were antigenic and immunogenic if the peptide was targeted to the ER, expressed in the cytosol with short flanking sequences, or expressed from within a self-protein, murine dihydrofolate reductase. (
  • MabCampath is a monoclonal antibody that specifically recognises and binds to a unique protein located on the surface of abnormal lymphocytes. (
  • In vitro experiments conducted with murine bone marrow derived macrophages demonstrated that after 24 h of treatment with the PLGA-encapsulated CRISPR plasmids, the majority of cells were positive for TIPS pentacene and the protein Cas9 was detectable within the cells. (
  • Monoclonal antibody 1D8 ( ATCC VR-1642 ) reacts specifically with influenza A virus H9 hemagglutinin by ELISA against recombinant proteins. (
  • [ 13 ] However, ATG, as well as other immunosuppressive foreign proteins, such as chimeric monoclonal antibodies that consist of murine-derived antigen-binding fragment (Fab) and human-derived crystallizable fragment (Fc) portions of antibodies, have been reported to be sufficiently immunogenic to cause serum sickness. (
  • Mononine ® is purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of immunoaffinity chromatography. (
  • A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. (
  • 1. A monoclonal antibody of the class IgG or IgM, derived from the fusion of a murine myeloma cell and a murine antibody-producing lymphoid cell, demonstrating specific reactivity to a phosphotyrosine moiety on phosphotyrosine-containing proteins. (
  • 2. The monoclonal antibody of claim 1 wherein the antibody demonstrates positive detection of antigenic determinants of phosphotyrosine-containing proteins by immunosorbent and electrophoretic assays. (
  • 5. The antibody of claim 1 wherein the antibody demonstrates positive reactivity with phosphotyrosine-containing proteins from animal cells. (
  • 7. A murine hybridoma cell line characterized by its production of monoclonal antibodies of the class IgG or IgM demonstrating specific reactivity to a a phosphotyrosine moiety on phosphotyrosine-containing proteins. (
  • 8. The cell line of claim 7 wherein the antibodies demonstrate positive detection of antigenic determinants of phosphotyrosine containing proteins by immunosorbent and electrophoretic assays. (
  • 11. The cell line of claim 7 wherein the antibodies demonstrate positive reactivity with phosphotyrosine-containing proteins from animal cells. (
  • h5G1.1-mAb is a genetically engineered antibody that blocks the activity of certain proteins involved in the immune reaction that produces inflammation. (
  • Search, Find and Buy Antibodies, ELISA Kits and Proteins. (
  • Further, monoclonal antibodies are only able to recognize specific proteins present of the cell surface. (
  • Using granulocytes as the source of effector cells, FcαRI-engagement can induce potent antibody-dependent cellular cytotoxicity (ADCC) against tumor cells [ 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ]. (
  • gp75) and active immunization with plasmid DNA encoding altered Tyrp1 both mediate tumor immunity in the B16 murine melanoma model. (
  • In conclusion, TA99 enhances DNA vaccination against both the target antigen Tyrp1 and a distinct melanoma antigen gp100 in an Fc receptor-dependent mechanism, consistent with enhanced cross-presentation of tumor-derived antigen. (
  • NO:7 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9, wherein said humanized antibody binds prostate stem cell antigen (PSCA), and wherein administration of said humanized antibody to a subject diagnosed with prostate cancer decreases tumor growth to a greater extent than treatment with the murine 1G8 monoclonal antibody. (
  • Indirect Immunoperoxidase Staining of Tumor Specimens of Monoclonal Antibodies 7E11C5. (
  • The monoclonal antibodies exhibit a high level of binding to human prostatic cancer cells and normal prostatic epithelium and are potentially capable of experimental in vivo tumor localization. (
  • Moreover, even in the absence of adjuvant, immunization with this glycosidic Tn-based vaccine induced high levels of anti-Tn antibody responses, recognizing human tumor cells. (
  • All five human monoclonal antibodies produced 2.4 to 44 µg/ml of immunoglobulin M, had a similar but not identical pattern of reactivity against a panel of human tumor cell lines, and failed to react with normal human astrocytes. (
  • The treatment of anti-PD-1/GITR mAb increased the frequencies of interferon-γ-producing effector T cells and decreased immunosuppressive regulatory T cells and myeloid-derived suppressor cells, shifting an immunosuppressive tumor milieu to an immunostimulatory state in peritoneal cavity. (
  • More importantly, combined treatment of anti-PD-1/GITR mAb and chemotherapeutic drugs (cisplatin or paclitaxel) further increased the antitumor efficacy with 80% of mice obtaining tumor-free long-term survival in murine ID8 ovarian cancer and 4 T1 breast cancer models. (
  • The use of monoclonal antibodies targeting these immune checkpoints has been shown to promote anti-tumor immune responses clinically. (
  • 14] The murine antiepidermal growth factor antibody M225, from which cetuximab was derived by chimerization, substantially enhanced the antitumor effects of doxorubicin in established xenografts of EGFR-expressing tumor cells. (
  • ADCETRIS comprises an anti-CD30 monoclonal antibodyanti-CD30 monoclonal antibody and a cytotoxic (cell-killing) agent that is released upon internalization into CD30-expressing tumor cells. (
  • Overexpression of p97 in melanoma as compared with normal tissue, in conjunction with the greater sensitivity of tumor cells to L49-vcMMAF, supports further evaluation of antibody-drug conjugates for targeting p97-overexpressing tumors. (
  • Cetuximab (C225, IMC-225) was developed as a human-murine chimeric antibody derived from the murine antibody M225, which binds specifically to the ligand-binding domain of EGFR. (
  • The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. (
  • Ranibizumab (Lucentis) is a Fab fragment (approximate M.W. 48 KDa) of a humanized IgG1 kappa murine monoclonal antibody that binds activated forms of vascular endothelial growth factor (VEGF-A). This prevents binding of VEGF-A to its receptors (VEGFR1 and VEGFR2) on vascular endothelium and thereby prevents vascular endothelial proliferation, vascular leakage and neo-vascularization. (
  • The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). (
  • Immunohistochemistry-Paraffin: CD25/IL-2 R alpha Antibody (OX-39) [ABIN2557811] - Rat lymph node cryosection with Mouse anti Rat CD25 followed by horseradish peroxidase conjugated Goat anti Mouse IgG1 as a detection reagent. (
  • The antibody is an IgG1-κ that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE. (
  • Natural murine autoantibodies and conventional antibodies exhibit similar degrees of antigenic cross-reactivity. (
  • The autoantibodies and conventional antibodies produced in splenic fragment cultures by normal DBA/2 and autoimmune NZB B cells expressed similar degrees of antigenic cross-reactivity. (
  • Plasma titers of such antibodies are correlated with atherosclerosis in murine models, and several such autoantibodies have been cloned. (
  • To understand the potential role(s) that such autoantibodies to OxLDL play in atherogenesis in humans, we prepared a human phage display combinatorial library to generate monoclonal autoantibodies to epitopes of OxLDL. (
  • Professor Utz is an expert in the study of human and murine autoantibodies and autoantigens, apoptosis signaling pathways, animal models of autoimmunity, proteomics and multiplexed assay development for biomarker discovery. (
  • The IgA antibodies exhibited potent Fab- and Fc-mediated functionalities against cancer cell lines, whereby especially granulocytes are recruited. (
  • CD73-derived adenosine acts as potent inhibitor of inflammation, and regulatory T cells (Treg) have been shown to express CD73 as a novel marker. (
  • In vivo DC-targeting strategies, based on Tn-MGL interactions, constitute a promising strategy for enhancing antigen presentation and inducing potent antibody response. (
  • Alemtuzumab is a potent monoclonal CD52 antibody used to treat patients with multiple sclerosis (MS). However, recent literature reports have described paradoxical activation of B cell-mediated diseas. (
  • Thus, even 43 years after circulation of H2N2 viruses, these subjects possessed peripheral blood B cells encoding potent inhibiting antibodies specific for a conserved region on the globular head of the pandemic H2 HA. (
  • Novel approaches in the passive immunization strategy include antibody drug conjugates, a combination of targeting antibody with a very potent drug such as the recently approved brentuximab vedotin (ADCETRIS™) for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). (
  • Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," Eur. (
  • 4. An immunoconjugate according to claim 1, wherein the antibody comprises the hypervariable region from an antibody capable of binding to an antigen with an affinity constant of at least 10 11 l/mol and having a cross reactivity of less than 11%, and a constant region from a human antibody. (
  • 13. An isolated human antibody, or an antigen binding portion thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:2. (
  • 19. A recombinant human antibody, or antigen-binding portion thereof, that neutralizes the activity of human TNFalpha but not human TNFß and has the identifying characteristics of an antibody as defined in anyone of claims 1 to 18. (
  • 42. A method of synthesizing a human antibody that binds human TNFalpha, comprising culturing the host cell of claim 41 in a culture medium until a human antibody that binds human TNFalpha is synthesized by the cell. (
  • A monoclonal antibody composed of the variable region of a murine antibody and the constant region of human antibody. (
  • A murine monoclonal antibody to human C5, m5G1.1-mAb, was humanized (h5G1.1-mAb) by grafting the antibody's antigen-binding CDR regions onto human antibody-derived framework and constant domains. (
  • Investigation of the human antibody response to the 1957 pandemic H2N2 influenza A virus has been largely limited to serologic studies. (
  • IgA antibodies have great potential to improve the functional diversity of current IgG antibody-based cancer immunotherapy options. (
  • Once cloned, cell lines can be maintained continuously to produce an unlimited homogeneous monoclonal antibody population that can be isolated and/or purified and used clinically for in vitro immunohistological, immuno-cytological or immuno-serological diagnosis, in vivo diagnosis by localization of tumors and metastases, and immunotherapy of human cancers, particularly those of the prostate. (
  • Immune responses, including antibodies and T cells to oregovomab and CA125, were demonstrated in over half the patients. (
  • Dendritic cells (DC) pulsed with antigen-antibody complexes (immune complexes, IC) containing ovalbumin are a more effective vaccine against ovalbumin expressing B16 than are DCs pulsed with ovalbumin alone ( 7 ). (
  • Given the fact that each immune serum is an extensive mixture of anti-H-2 antibodies with different specificities, the isolated McAbs can be seen as illustrative examples which explain the reaction pattern of the immune sera. (
  • When the antigen and antibody molecules are present in approximately equal molar ratios (slight antigen excess), known as the zone of equivalence, cross-linking and lattice formation occur forming intermediate and large immune complexes. (
  • Naturally occurring human monoclonal antibodies can help us understand the protective and pathogenic roles of the humoral immune system in dengue virus infection. (
  • A substance that, when introduced into the body, signals the immune system to produce antibodies. (
  • The human immune system has the ability to create millions of different antibodies with high affinity to the target molecules. (
  • Here, we report on the ability of human monoclonal antibodies and immune sera derived from dengue patients to neutralize contemporary epidemic ZIKV strains. (
  • In general, antibodies are significant elements of the body's adaptive immune system. (
  • After binding, cancer cells can be destroyed by different mechanisms such as antibody-dependent cellular cytotoxicity, the activation of the complement system -- an important part of the immune system -- and triggering cell death. (
  • Fremanezumab is a humanised monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. (
  • Omalizumab is a humanised monoclonal antibody manufactured by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell line. (
  • Pioneering research by Coller and colleagues with a murine derived monoclonal antibody directed against the GP IIb/IIIa receptor 5 led to the development of a chimeric monoclonal antibody Fab fragment compound known as c7E3 Fab or abciximab (Reopro). (
  • Induction of virus-specific antibody production by lamina propria lymphocytes following intramuscular inoculation with rotavirus. (
  • Demyelinating lesions are associated with infiltrating T lymphocytes, bone marrow-derived macrophages (BMDM), and activated resident microglia. (
  • Patients were monitored by serial clinical assessments, flow cytometry of peripheral blood B lymphocytes and antibody testing. (
  • On murine T lymphocytes the A2aR is highly expressed ( 20 ), and after T-cell receptor (TCR) stimulation, A2aR mRNA levels increase by a factor of ∼10 ( 16 ). (
  • Katz, D.H. Skidmore B.J., Katz, L.R., and Bogowitz C.A.: Adaptive differentation of murine lymphocytes. (
  • I. Both T and B lymphocytes differentiating in F1' parental chimeras manifest preferential cooperative activity for partner lymphocytes derived from the same parental type corresponding to the chimeric host. (
  • Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. (
  • use ADCC (antibody-dependent cytotoxicity) to recognize IgG and induce apoptosis in infected cells. (
  • Antibody‐dependent cell‐mediated cytotoxicity (ADCC) is an immunologic cytotoxic effector mechanism that is dependent on the cooperative interaction of humoral and cellular effector elements. (
  • In this form of cytotoxicity, effector cells with receptors for the Fc portion of immunoglobulin produce target cell lysis by attachment to the Fc portion of antibodies that are bound to target cells via their antigen‐combining sites. (
  • Identifying factors that determine the sensitivity or resistance of cancer cells to cytotoxicity by antibody-drug conjugates is essential in the development of such conjugates for therapy. (
  • Thus, for antibody-drug conjugates targeting p97, antigen level and trafficking to the lysosomes are important factors for achieving robust in vitro cytotoxicity against cancer cells. (
  • Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. (
  • The antigenic target of Antibody MVS-1, identified by immunoblotting techniques, contained a polypeptide of relative molecular mass (Mr) approx. (
  • When the antigenic target of Antibody MVS-1 was chormatographed in potassium phosphate buffer, the position of elution corresponded to that of a high-molecular-weight species (Mr 400,000). (
  • Human monoclonal antibodies derived from patients with astrocytic tumors might recognize subtle antigenic specificities that would differ from those recognized by xenogeneic (murine) systems. (
  • The citrulline-reactive monoclonal antibodies did not react with the unmodified arginine peptides, yet several reacted with more than one citrullinated antigen. (
  • A role for active antigen selection of the citrulline-reactive synovial B cells was supported by the strong bias toward amino acid replacement mutations in ACPA + antibodies and by their loss of reactivity to citrullinated autoantigens when somatic mutations were reverted to the corresponding germline sequences. (
  • However, cross-reactive antibodies can complicate flavivirus diagnostics and promote more severe disease, as noted after serial dengue virus (DENV) infections. (
  • In this study, epitopes of LDL (-) were mapped using a phage display library of peptides and monoclonal antibodies reactive to this modified lipoprotein. (
  • To determine the effect of humanized monoclonal antibody against α4 integrin (reactive with α4β1 integrin or very-late antigen-4) on MRI lesion activity in MS. (
  • The antibody preparation supplied is affinity purified from serum free supernatants of cultured cells. (
  • The immunoconjugate of the invention comprises a monoclonal antibody having an affinity of at least 10 11 l/mol and a cross-reactivity of less than 10%, and a neutron capture agent. (
  • More preferably, the affinity of the monoclonal antibody is at least 10 12 l/mol. (
  • A murine monoclonal antibody to Factor IX is used as an affinity ligand to isolate Factor IX from the source material. (
  • Previous studies have demonstrated that ELISA assays of splenic fragment culture supernatants detect antibodies with affinities of 5 x 10(6) M-1 or greater. (
  • Monoclonal antibodies were secreted by the transferred B cells in splenic fragment cultures. (
  • Active demyelinating lesions are characterized by CD8 T cells, CD4 T cells expressing both Th1 and Th17 cytokines, bone marrow-derived macrophages (BMDM) and activated CNS resident microglia ( 1 , 2 ). (
  • This study explored the role of endogenously formed adenosine in modulating NF-κB activity and cytokine/chemokine release from murine Treg and effector T cells (Teff) including key enzymes/purinergic receptors of extracellular ATP catabolism. (
  • In summary, CD73-derived adenosine tonically inhibits active NF-κB in CD4 + T-cells, thereby modulating the release of a broad spectrum of proinflammatory cytokines and chemokines. (
  • Antibodies modulate T-cell responses in infectious disease, autoimmunity, and cancer through Fc domain interactions with surface receptors on antigen presenting cells ( 6 ). (
  • Anti-her-2/neu monoclonal antibody (mAb) therapy has moreover been shown, in vivo , to improve uptake of cellular vaccines, and subsequent antigen presentation by DCs to CD8+ T cells ( 8 , 9 ). (
  • [ 27 ] This monoclonal antibody attacks a frizzled homologue called FZD10 (a cell-surface receptor), which is present in synovial sarcoma cells and absent in normal organs. (
  • Two alloreactive H-2 (class I) specific cytotoxic IgM monoclonal antibodies (McAbs), B6-1 and B6-2, were isolated from C57B1/6 (B6) mice after injections of syngeneic Sendai virus-coated (SV+) spleen cells. (
  • Froscher, B.G., and Klinman, N.R.: Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonale antibodies. (
  • Because the antibody also binds to peripheral nerve cells, the treatment is painful, but it is generally without long-term complications. (
  • Most developmentally regulated epitopes identified on embryonal carcinoma cells and murine preimplantation embryos are associated with a glycoprotein-bound large glycan called embryoglycan. (
  • To prepare monoclonal antibodies recognizing other, less immunogenic stage-specific embryonic epitopes, we used embryoglycan-negative embryonal carcinoma cells P19XT.1.1 as immunogen. (
  • Splenocytes, derived from mice that had been immunized with protoplasts prepared from suspension cultures of root cells of Glycine max (L.) Merr. (
  • Results: The blockade of PDGFRα on prostate cancer cells by IMC-3G3 reduces the size of established skeletal metastases, whereas the IMC-1E10 antibody directed against the stromal PDGFRα fails to inhibit metastatic progression. (
  • To address these questions, we have used a single B cell-based cloning technology to isolate and express immunoglobulin (Ig) genes from joint-derived B cells of active RA patients. (
  • We found ∼25% of synovial IgG-expressing B cells to be specific for citrullinated autoantigens in the investigated ACPA + RA patients, whereas such antibodies were not found in ACPA − patients. (
  • This unit describes an assay of ADCC activity that can be used as a test for immunocompetence in effector cells or to test the activity of a monoclonal antibody to mediate ADCC. (
  • Class of specific cytotoxic cells demonstrated in vitro by arming with antigen‐antibody complexes. (
  • In vitro, PI3Kδi-induced substantive apoptosis and disrupted microenvironment-derived signaling in murine (Eμ-Tcl1) and human (CLL) leukemia cells. (
  • Previously, 4T1 has been associated with high expression of granulocyte-colony stimulating factor (G-CSF) systemically resulting in increased extramedullary hematopoiesis and the accumulation of myeloid derived suppressor cells (MDSCs). (
  • To characterize more completely this binding we evaluated interactions between CD36 and Ox-LDL in murine NIH-3T3 cells stably transfected with human CD36 cDNA. (
  • Binding of Ox-LDL to CD36-transfected 3T3 cells was inhibited by a panel of anti-CD36 antibodies and by soluble CD36 but not by thrombospondin. (
  • Macrophage-derived cholesteryl ester-laden foam cells are a characteristic feature of the atherosclerotic lesion. (
  • However, it is found on both hepatoma and lymphoma cells in vitro, and on in vivo tumours from murine sources. (
  • B7.1 and B7.2 are expressed by all bone marrow-derived APCs including B cells, macrophages, and DCs, although at different ratios and with different kinetics. (
  • Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. (
  • SeV's ability to fuse eukaryotic cells and to form syncytium was used to produce hybridoma cells capable of manufacturing monoclonal antibodies in large quantities. (
  • In this article, we analyze the results of cryo-electron tomography experiments performed on monoclonal murine IgG2a antibodies. (
  • Murine monoclonal antibodies (MMAbs) targeting domain I epitopes tend to be non-neutralizing. (
  • However, human-derived monoclonal antibodies to epitopes of oxidized LDL (OxLDL) have not yet been reported. (
  • The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. (
  • Today, all approved monoclonal antibodies for cancer therapy are immunoglobulin (Ig) G isotype antibodies [ 1 , 2 ]. (
  • Immunoglobulin M (IgM) antibodies usually develop 7-14 days after immunization with the antigen. (
  • the improvement wherein the second monoclonal antibody is of a different immunoglobulin class or subclass than the immobilized monoclonal antibody. (
  • Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE). (
  • The resulting hybridoma cultures were screened for the production of antibodies directed against the soybean protoplasts and were then cloned. (
  • To gain a more thorough understanding of the humoral aspect of this autoimmunity, we investigated the cellular and molecular basis of the production of antibodies to various citrullinated autoantigens in RA patients. (
  • A type of white blood cell involved in the production of antibodies. (
  • Characterization of neuraminidase-resistant mutants derived from rotavirus porcine strain OSU. (
  • Characterization of monoclonal antibody's binding kinetics using oblique-incidence reflectivity difference approach. (
  • Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. (
  • In addition to surgery, chemotherapy and radiation, many neuroblastoma patients at MSKCC were treated with a murine (mouse-derived) monoclonal antibody called 3F8. (
  • The spec only refers to murine (mouse derived) monoclonal antibodies. (
  • We constructed a phage display antibody library from a patient with high plasma anti-MDA-LDL titers and isolated 3 monoclonal IgG Fab antibodies, which specifically bound to MDA-LDL. (
  • Antibodies produced in response to infection with any of the four serotypes of dengue virus generally provide homotypic immunity. (
  • Role of anaphylactic antibodies in immunity to schistosomes. (
  • Antibodies to flaviviruses can be protective, resulting in lifelong immunity to reinfection by homologous virus. (
  • 6,7 We have recently cloned monoclonal antibodies to oxidized LDL (OxLDL) from apoE −/− mice 5 and have shown that they not only bind to OxLDL but also block the uptake of OxLDL by macrophages. (
  • We demonstrate that an anti-CD36 monoclonal antibody inhibited 50% of the specific binding and 26% of the specific degradation of Ox-LDL by human monocyte-derived macrophages. (
  • The blockage of either TLR4 or LOX-1 decreased IL-1ß and IL-18 secretion by human-derived macrophages as both pathways are necessary for complete inflammasome activation. (
  • P1A3 or P2C7 were quickly internalized by bone marrow-derived murine macrophages as shown by confocal microscopy. (
  • P2C7 increased the expression of TNFα, IL-1 ß and iNOS as well as the secretion of TNFα, CCL2, and nitric oxide by murine macrophages, similar to the responses induced by LDL (-), although less intense. (
  • Using poly(lactic- co -glycolic acid) (PLGA), a nanoparticle carrier was designed to deliver a model CRISPR-Cas9 plasmid into primary bone marrow derived macrophages. (
  • In this work, plasmids for the CRISPR-Cas9 system were encapsulated in nanoparticles comprised of PLGA and were shown to induce expression of bacterial Cas9 in murine bone marrow derived macrophages in vitro. (
  • Humanization of murine monoclonal antibodies by replacing of certain parts of the antibody with human sequences has improved the tolerability of antibodies and made them less immunogenic, but even fully human sequence-derived antibodies can carry some immunological risk. (
  • SB-1 cell line), were fused with a murine myeloma cell line. (
  • Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). (
  • Among all tested peptides, two circular peptides, P1A3 and P2C7, were selected based on their high affinities for the monoclonal antibodies. (
  • However, genetic deletion of CD73 in mice is associated with a proinflammatory phenotype and CD73-derived adenosine appears to be quantitatively sufficient to inhibit platelet activation, and leukocyte adhesion to the vascular endothelium in vivo ( 15 ) by acting through the A2aR ( 47 ). (
  • Furthermore, we demonstrated the prolonged in vivo efficacy of the lead antibody with a single administration in mice and cynomolgus monkeys. (
  • Accordingly, Bim−/− Eμ-Tcl1 Tg leukemias demonstrated resistance to PI3Kδi-induced apoptosis were refractory to PI3Kδi in vivo and failed to display combination efficacy with anti-CD20 monoclonal antibody therapy. (
  • In vivo experiments in transgenic and knockout mice have confirmed a role for B7h/B7RP-1 in effector responses, particularly involving antibody production ( 21 )( 22 )( 23 )( 24 ). (
  • Morphological, histological and immunohistological improvements were observed in vivo using murine IH model in which HemSCs and HUVECs were implanted into BALB/c-nu mice that were post-injected with E2. (
  • Calabresi, PA 2017, ' B-cell depletion - A frontier in monoclonal antibodies for multiple sclerosis ' New England Journal of Medicine , vol 376, no. 3, pp. 280-282. (
  • An oxidant-generating coupled-enzyme system-based, topical solution comprised of two enzymes, Aspergillus niger-derived glucose oxidase (GO) and porcine myeloperoxidase (p-MPO), as well as glucose, sodium chloride and stabilizing amino acids, with potential broad-spectrum microbicidal activity. (
  • Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. (
  • The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. (
  • Synagis is a composite of human (95%) and murine (5%) antibody sequences. (
  • Despite many reports suggesting different functions of B7.1 and B7.2 in Th1/Th2 differentiation, antibody production, and CTL generation ( 10 )( 11 )( 12 )( 13 ), their distinct immunologic roles remain to be clarified ( 14 )( 15 )( 16 ). (
  • Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. (
  • Auf finden Sie aktuell 561 Platelet-Derived Growth Factor Receptor, alpha Polypeptide (PDGFRA) Antikörper von 31 unterschiedlichen Herstellern. (
  • A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). (
  • Second, we targeted the stromal PDGFRα with IMC-1E10, an antibody specific for the murine receptor. (
  • The addition of 2B5 to [3H]PGE2 blocked the binding of radioligand to cell membranes transfected with the murine EP3 prostaglandin receptor. (
  • Monoclonal antibodies to the epidermal growth factor receptor (EGFR) are among the promising novel targeted therapies being explored in colorectal cancer. (
  • Antibody-bound receptor is internalized, albeit by an alternative and possibly slower process than is ligand-bound receptor. (
  • Autoimmune antibodies to IgE and its receptor, FcεRI, have been isolated from the serum of some patients with CSU. (
  • Antibody selection platforms include ribosome, mRNA, yeast cell and phage display (3). (
  • Clinical applications of these monoclonal antibodies are not yet available. (
  • The monoclonal antibodies of this invention possess distinctive characteristics and capabilities which make them suitable for in vitro clinical diagnostic and prognostic purposes. (
  • We therefore also analyzed the cross-reactivity of monoclonal antibodies derived from hybridomas. (
  • These antibodies show different patterns of cross-reactivity, neutralizing, and enhancement activity. (
  • 45. A method for inhibiting human TNFalpha activity in vitro comprising contacting human TNFalpha with the antibody, or an antigen-binding portion thereof, of any of claim 1 22 such that human TNFalpha activity is inhibited. (
  • The quality of an in vitro library is characterised by its ability to generate large populations of highly diverse and functional antibodies. (
  • C ) OIRD sensorgrams of 9 antigen-antibody interactions obtained simultaneously in a single reaction chamber. (
  • Ranibizumab was derived from the same murine monoclonal antibody as Bevacizumab (Avastin). (
  • A clear survival advantage has been demonstrated for the addition of bevacizumab (Avastin), a monoclonal antibody that targets the vascular endothelial growth factor (VEGF). (
  • However, prior infection or circulating maternal antibodies can also mediate a non-protective antibody response that can enhance the course of disease in a subsequent heterotypic infection. (
  • A murine monoclonal antibody specific for glycoprotein (GP)IIIa was prepared by immunization with a GPIIb- and GPIIIa-enriched Triton X-114 extract of platelet membranes. (
  • The CD4 T cell-induced autoimmune murine model of MS, experimental autoimmune encephalitis (EAE), in which BMDM are essential for demyelination, has revealed pathogenic and repair-promoting phenotypes associated with BMDM and microglia, respectively. (
  • The use of monoclonal antibodies targeting IgE, such as omalizumab, has proven very effective in improving respiratory symptoms and quality of life, while reducing asthma exacerbations, emergency room visits and the use of systemic corticosteroids in allergic severe asthma. (
  • Omalizumab, a humanized monoclonal antibody manufactured from a mammalian cell line. (
  • The 9E5 antibody will also be useful in medicine as a neutralizing antibody specific for colon cancer. (
  • Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. (
  • Several approaches of inhibiting Gal-1 were currently under research, such as blockade of CRD using oligosaccharides and specific monoclonal antibodies. (
  • Natural autoreactive H-2 specific antibodies. (
  • Identification of a monoclonal antibody specific for a murine T3 polypeptide. (
  • A monoclonal antibody (145-2C11) specific for the murine T3 complex was derived by immunizing Armenian hamsters with a murine cytolytic T-cell clone. (
  • More particularly, this invention relates to monoclonal antibodies against non-soluble, membrane associated, organ specific determinants expressed maximally on human normal and neoplastic prostatic epithelium. (
  • A previously described monoclonal antibody specific for the GPIIb/IIIa complex (AP- 2) inhibited platelet aggregation induced by ADP, thrombin, collagen, or arachidonic acid (Pidard et al, J Biol Chem 258:12582-12586, 1983). (
  • In contrast, AP-3 had no effect on aggregation induced by any of these reagents, a finding similar to that previously reported for the GPIIb- specific monoclonal antibody, Tab (McEver et al, J Clin Invest 66:1311- 1318, 1980). (
  • Antibodies, also known as immunoglobulins, are characterised by their specific Y shaped structure. (